Document:

ANTIGENICS CONSENT AGREEMENT

 Exhibit 10.15 
 Antigenics Consent Agreement 
 Dated as of February 28, 2007 
 GENERAL ELECTRIC CAPITAL CORPORATION 
 83 Wooster Heights Road 
 Fifth Floor 
 Danbury, CT 06810 
  

	 	Re:	(a) Sublease Agreement dated July 16, 2002, by and between Antigenics, Inc., a Massachusetts corporation, as sublandlord (“Sublandlord”), and GTC Biotherapeutics, Inc., a
Massachusetts corporation, as subtenant (“Tenant”), as amended by First Amendment to Sublease dated March 16, 2004 (as so amended and as affected by that that certain Consent to Sublease dated as of July 18, 2002, among Sublandlord, Tenant
and NDNE 9/90 Corporate Center LLC, the “Sublease”), pertaining to certain premises located at 175 Crossing Boulevard, Framingham, Massachusetts (the “Premises”); and 

 (b) Antigenics Leasehold Lease dated July 19, 2002, by and between Sublandlord and Tenant, as amended by First Amendment to Leasehold Lease dated as of
March 16, 2004 (as so amended, the “Leasehold Lease”, and, together with the Sublease, the “Leases”). 
 Ladies and Gentlemen:

 The Tenant has informed the Sublandlord that General Electric Capital Corporation (the “Financier”), has extended a lease, loan
and/or other credit facilities (as the same may be hereafter amended, modified or replaced, collectively, the “Financing”) to the Tenant, and that the Tenant has agreed to obtain this Antigenics Consent Agreement from the Sublandlord. The
Sublandlord understands that in connection with the Financing, the Tenant and the Financier have entered into a lease, security agreement and/or similar agreements (the “Financing Agreements”) whereby, among other things, the Tenant has
granted to the Financier a security interest in all of the Tenant’s tangible and intangible personal property other than the Tenant’s intellectual property (the “Collateral”), and the Financier shall have ownership of, a first
lien on or other paramount rights to the equipment and other property described in the Financing Agreements (together with the Collateral, the “Personal Property”), subject only to the Tenant’s rights therein as provided in the
Financing Agreements. The Personal Property, as defined herein, shall not include, without limitation, any security deposit delivered to the Sublandlord as security for the Tenant’s obligations under the Leases, any fixtures or equipment owned
by the Landlord or the Sublandlord which constitutes a part of the Property or any Property systems such as heating, ventilation, air-conditioning, plumbing, mechanical, electrical, or other equipment that is so affixed or related to the real estate
that it constitutes real property. 
 Sublandlord hereby certifies and confirms to and agrees with the Financier and the Tenant as follows:

 1. The Sublandlord hereby consents to the Tenant’s grant to the Financier of a security interest in the Personal Property, to the
extent that the interest of the Financier in the Personal Property constitutes a security interest under applicable law, and subordinates to the Financier any and all liens and all rights which the Sublandlord now has or may hereafter acquire in the
Personal Property related to the Financing, whether by contract or otherwise, and agrees that the Personal Property is and shall remain personal property of the Tenant or the Financier, as applicable, at all times while the Financing remains
outstanding. 

 2. Subject to the rights of Tenant, the Sublandlord at all times during the term of the Leases consents
to the entry by Financier and its agents and representatives onto the Premises to inspect, remove or dispose of the Personal Property, provided, that, during such period of entry, Financier shall pay to Sublandlord any basic rent and
additional rent due under the Sublease pro-rated on a per diem basis determined on a 30-day month if Tenant is in default of its obligations to pay such amounts to Sublandlord, and shall provide and retain liability and property insurance coverage,
electricity and heat to the extent required by the Sublease if Tenant is in default of its obligations under the Sublease to provide any of such items, and such amounts paid by Financier to Sublandlord shall exclude any rent adjustments, indemnity
payments or similar amounts for which the Tenant remains liable under the Leases for default, holdover status or other similar charges. In no event, however, shall the Financier (or any of its agents, contractors or employees) conduct a public or
private sale of such Personal Property on the Premises, provided that nothing set forth herein shall restrict prospective buyers accompanying a representative of Financier to the Premises to appraise the Personal Property for potential purchase on
the condition that not more than one prospective buyer accompany the Financier at any one time. In the event the Sublease shall be terminated for the Tenant’s default or otherwise, Sublandlord shall, either before or after such termination,
give the Financier notice of such termination, and the Financier or its representatives shall have the right to enter onto the Premises for the purposes provided in the first sentence of this paragraph 2 for a period not exceeding twenty (20) days
after receipt of such notice, provided the Financier and its agents and representatives are insured, and provided that for the period that the Financier occupies the Premises, the Financier shall shall pay to Sublandlord any basic rent and
additional rent due under the Sublease pro-rated on a per diem basis determined on a 30-day month if Tenant is in default of its obligations to pay such amounts to Sublandlord, and shall provide and retain liability and property insurance coverage,
electricity and heat to the extent required by the Sublease if Tenant is in default of its obligations under the Sublease to provide any of such items, and such amounts paid by Financier to Sublandlord shall exclude any rent adjustments, indemnity
payments or similar amounts for which the Tenant remains liable under the Leases for default, holdover status or other similar charges. The Financier hereby agrees that in the event that any of the Personal Property remains in the Premises after the
termination of the Sublease, subject to Financier’s rights herein to enter the Premises as aforesaid, at the Sublandlord’s option, the Personal Property may thereafter be removed and retained or disposed of by the Sublandlord subject to
the Financier’s lien. 
 3. In the event that the Financier shall enter or remove any or all of the Personal Property from the Premises,
the Financier shall repair any damage to the Premises resulting from Financier’s entry onto the Premises or removal of the Personal Property. The Financier shall indemnify and hold harmless Sublandlord from and against all loss, cost, liability
and expense, including reasonable attorneys’ fees, resulting from actions of the Financier or its representatives in connection with its or their entry onto the Premises or the Financier’s removal of the Personal Property therefrom.
Nothing set forth herein shall require the Financier to indemnify or hold Sublandlord harmless for any loss, cost, liability or expense arising out of or resulting from the Sublandlord’s intentional misconduct or gross negligence. Any
authorized entry by the Financier will be conducted in a manner that will not unreasonably disrupt the activities of any of the tenants or occupants of the Property of which the Premises is a part. 
 4. No action by Financier pursuant to this Antigenics Consent Agreement shall be deemed to be an assumption by Financier of any obligation under the
Leases, and, except as expresssly provided in this Antigenics Consent Agreement, Financier shall not have any obligation to Sublandlord. 
 5. Tenant consents to all of the terms and conditions of this Antigenics Consent Agreement. 
  

 2 

 6. The Sublandlord has not assigned, transferred or hypothecated its interest under the Leases such that
Sublandlord would not have the full right, power and authority to execute and deliver the within consent. 
 7. This Antigenics Consent
Agreement shall be governed and controlled by and interpreted under the laws of the Commonwealth of Massachusetts and shall inure to the benefit of and be binding upon the successors, heirs and assigns of the Sublandlord, the Tenant and the
Financier. 
 8. Whenever, by the terms of this Agreement, notices are to be given to any party, such notices shall be in writing and shall
be sent by registered or certified mail, postage pre-paid, return receipt requested, or by a recognized overnight delivery service such as Federal Express. Any such notice shall be effective upon delivery, attempted delivery or refusal whichever
shall first occur. 
 9. Nothing contained herein shall modify, amend or release any of the obligations of the Tenant under the Leases, and
the Tenant shall remain fully and completely liable and obligated with respect thereto. 
 10. This Agreement may be executed in any number
of counterparts, each of which shall constitute an original for all purposes. 
  

			
	 GTC BIOTHERAPEUTICS, INC.,
 a Massachusetts
corporation

		
	By:	 	/s/ John B. Green, Jr.
	Name: John B. Green, Jr.
	 Title: Senior Vice President, Chief Financial
 Officer and Treasurer

	
	 GENERAL ELECTRIC CAPITAL
 CORPORATION

		
	By:	 	/s/ Danijela Gjenero
	Name: DANIJELA GJENERO
	Title: DULY AUTHORIZED SIGNATORY
	
	ANTIGENICS, INC.
		
	By:	 	/s/ John Cerio
	Name: John Cerio
	Title: Vice President

  

 3Amendment No. 1,2,3,5,6 and 7 to Exclusive License Agreement with Aronex Pharm.

 Exhibit 10.18.1 
 Amendment No. 1 
 to the Exclusive License Agreement of July 1, 1988 
 THIS IS AMENDMENT No. 1, dated March 12, 1990, to the Exclusive License Agreement of July 1, 1988 (hereinafter “Exclusive License
Agreement”) between the BOARD OF REGENTS of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter “BOARD”), a governing board established under the laws of the state of Texas, THE UNIVERSITY OF TEXAS SYSTEM CANCER CENTER (hereinafter
“UTSCC”), now THE UNIVERSITY OF TEXAS Mi). ANDERSON CANCER CENTER (hereinafter a component institution of THE UNIVERSITY OF TEXAS SYSTEM, and ARGUS PHARMACEUTICALS, INC. (hereinafter “ARGUS”), a Delaware corporation whose address
is 2202 Timberloch Place, Suite 118, The Woodlands, Texas 77380 (formerly 2170 Buckthorne Place, Suite 350-A, The Woodlands, Texas 77380). 
 WITNESSETH: 
 WHEREAS BOARD is the sole assignee, pursuant to an Agreement with The University of Houston dated
December 1, 1989, (the “Assignment Agreement”) of the U.S. patent application Serial Number [**] with an assigned filing date of [**], and also designated by MDA as [**], with named inventors [**]; and 
 WHEREAS ARGUS and MDA are also parties to a Research and Development Contract dated July 1, 1988, (hereinafter “R&D Contract”) related to the
Exclusive License Agreement; and 
 WHEREAS the subject matter of said patent application was conceived, discovered or reduced to practice during the term of
the R&D Contract by at least one of the Researchers/Inventors but not as the result of funding under the R&D Contract and, therefore, is NEW TECHNOLOGY as defined in the R&D Contract; and 
 WHEREAS MDA provided ARGUS with a New Technology Notice and ARGUS provided MDA with Notice of Interest in said NEW TECHNOLOGY pursuant to Paragraph 5.3 of the R&D
Contract; and 
 WHEREAS MDA and ARGUS have concluded negotiations for the acquisition by ARGUS of rights to said NEW TECHNOLOGY pursuant to Paragraph 5.3 of
the R&D Contract, 
 NOW, THEREFORE, the parties hereby agree to the following: 
 The Exclusive License Agreement is amended to include U.S. patent application Serial Number [**], filed [**], and the technology, inventions, know- how,
processes, and formulae relating thereto, within the definition of Board Patent Rights and Licensed Subject Matter as contained therein. Such patent application and technology are therefore subject to the license granted by MDA to ARGUS with respect
to BOARD Patent Rights, BOARD Technical Information, and Related Technology, and, except as otherwise provided herein, shall be governed by the terms of the Exclusive License Agreement in all respects. 
  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment
request. An unredacted version of this agreement has been filed separately with the Commission. 

 In consideration thereof, the sufficiency of which is hereby acknowledged, ARGUS shall pay royalties to MDA pursuant to
the royalty schedule of Article III of the Exclusive License Agreement on the sales of Products using said NEW TECHNOLOGY, provided, however, that MDA agrees to distribute such royalty payments in accordance with the terms of the Assignment
Agreement, and, to the extent authorized by the constitution and laws of the state of Texas, agrees to indemnify Argus from any liability for failure to do so. 
 Article XI, REPRESENTATIONS AND WARRANTIES, of the Exclusive License Agreement is not applicable to the NEW TECHNOLOGY that is the subject of this Amendment No. 1. 
 Except as provided herein, the terms of the Exclusive License Agreement are not affected by this Amendment No. 1 and shall remain in full force and effect. 
 IN WITNESS WHEREOF, the parties hereto have entered into this Amendment No. 1, effective as of the date hereinabove, and executed by their duly authorized
representatives three (3) original counterparts, each of which shall be considered an original. 
  

									
	THE UNIVERSITY OF TEXAS	 		 	ARGUS PHARMACEUTICALS, INC.
	MD ANDERSON CANCER CENTER	 		 	
					
	By:	 	 /s/ David J. Bachrach
	 		 	By:	 	 /s/ George Goldenberg

		 	David J. Bachrach	 		 		 	George Goldenberg
		 	 Executive Vice President
 for Administration and
Finance
	 		 		 	President
				
	APPROVED AS TO CONTENT	 		 		 	
					
	By:	 	 /s/ William Doty
	 		 		 	
		 	William Doty	 		 		 	
		 	Director, Technology Development	 		 		 	
				
	BOARD OF REGENTS OF THE	 		 		 	
	UNIVERSITY OF TEXAS SYSTEM	 		 		 	
					
	By:	 	 /s/ Michael E. Patrick
	 		 		 	
		 	Michael E. Patrick	 		 		 	
		 	Executive Vice Chancellor	 		 		 	
		 	For Asset Management	 		 		 	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 (09—12—90) 
 SCHEDULE I 
 TO 
 EXCLUSIVE LICENSE AGREEMENT 
 of July 1, 1988 
  

	1.	[**] Filed [**]. (UTSC: [**]) 

  

	2.	[**]. Filed [**]. (UTSC:[**]) 

  

	3.	[**], Filed [**] (UTCC: [**] – [**]) 

  

	4.	[**]. Filed [**]. (UTCC: [**] – [**]) 

  

	5.	[**]. Filed [**]. (UTSC: [**]) 

  

	6.	[**]. (UTSC: [**]) 

  

	7.	[**]. (UTSC: [**]) 

 Patents Sublicensed to Argus
Pharmaceuticals, Inc. Subject to Agreements Between The University of Texas M.D. Anderson Cancer Center and Ohio State University Research Foundation: 
  

	1.	[**],. U.S. Patent [**]. Filed [**]. 

  

	2.	[**], U.S. Patent No. [**]. Filed [**]. 

  

	3.	[**], U.S. Patent No. [**]. Filed [**]. 

  

	4.	[**], U.S. Patent No. [**]. Filed [**]. 

  

	5.	[**], U.S. Patent No. [**]. Filed [**]. 

  

	6.	[**], U.S. Patent No. [**]. Filed [**]. 

  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with
the Commission. 

 (09—12—90) 
 SCHEDULE I 
 TO 
 EXCLUSIVE LICENSE AGREEMENT 
 of October 15, 1986 
  

	1.	[**]. (UTSC: [**]) 

  

	2.	[**]. ([**]) 

  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Amendment No. 2 
 to the Exclusive License Agreement of July 1, 1988 
 THIS IS AMENDMENT No. 2, dated October 8, 1990,
to the Exclusive License Agreement of July 1, 1988 (hereinafter “Exclusive License Agreement”) between the Board of Regents of The University of Texas System (hereinafter “BOARD”), a governing board established under the
laws of the state of Texas, The University of Texas System Cancer Center (hereinafter “UTSCC”), now The University of Texas M.D. Anderson Cancer Center (hereinafter “MDA”), a component institution of The University of Texas
System, and Argus Pharmaceuticals, Inc. (hereinafter “ARGUS”), a Delaware corporation whose address is 3400 Research Forest Drive, The Woodlands, Texas 77381 (formerly 2202 Timberloch Place, Suite 118, The Woodlands, Texas 77380, formerly
2170 Buckthorne Place, Suite 350-A, The Woodlands, Texas 77380). 
 RECITATIONS: 
  

	1.	BOARD is the licensee with the right to sublicense of the patents 

 U.S. [**] issued [**]; 
 U.S. [**] issued [**] 
 U.S. [**] issued [**]; 
 U.S. [**] issued [**], 
 pursuant to an Agreement with the Ohio State University Research Foundation (“OSURF’) dated January 1, 1990, a copy of which is attached
hereto as Exhibit I; 
  

	2.	BOARD is the sublicensee with the right to further sublicense of the patents 

 U.S.[**] issued [**]; 
 U.S. [**] issued [**], 
 pursuant to an Agreement with OSURF dated June 15, 1990, a copy of which is attached hereto as Exhibit II, which are subject to a license agreement
between OSURF and The United States Department of Health and Human Services (“DHHS”); and 
  

	3.	The Agreements with OSURF referenced in the first two recitations above shall hereinafter be referred to the “OSURF Agreements”, and the patents referenced in the first
two recitations above shall hereinafter be referred to as the “Patents”; and 

  

	4.	The Exclusive License Agreement contemplates inclusion of the Patents within the Licensed Subject Matter as defined in the Exclusive License Agreement and therefore subject to the
license granted by MDA to ARGUS to BOARD Patent Rights, BOARD Technical Information, and Related Technology, 

  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with
the Commission. 

 NOW, THEREFORE, the parties hereby agree to the following: 
 The Exclusive License Agreement is amended to include BOARD’s rights with respect to the Patents within the Licensed Subject Matter as defined in the
Exclusive License Agreement and therefore subject to the license granted by MDA to ARGUS to BOARD Patent Rights, BOARD Technical Information, and Related Technology, subject to the terms and provisions of the OSURF Agreements and, for Patents U.S.
[**] issued [**], and U.S [**] issued [**], further subject to the provisions of the license agreement between OSURF and DHHS. 
 In
consideration thereof, the sufficiency of which is hereby acknowledged, ARGUS shall pay royalties to MDA pursuant to the royalty schedule of Article III of the Exclusive License Agreement on the sales of Products using the Patents. MDA shall pay
royalties directly to OSURF (as provided in the OSURF Agreements), subject to receipt by MDA of royalties from Argus on the sales of Products (as defined in the Exclusive License Agreement) using the Patents (as defined above in this Amendment 2).

 Article XI, REPRESENTATIONS AND WARRANTIES, of the Exclusive License Agreement is not applicable to the Patents that are the subject of
this Amendment No. 2. 
 Except as provided herein, the terms of the Exclusive License Agreement are not affected by this Amendment
No. 2 and shall remain in full force and effect. 
 IN WITNESS WHEREOF, the parties hereto have entered into this Amendment No. 2, effective as of
the date hereinabove, and executed by their duly authorized representatives three (3) original counterparts, each of which shall be considered an original. 
  

									
	THE UNIVERSITY OF TEXAS	 		 	BOARD OF REGENTS OF THE
	MD ANDERSON CANCER CENTER	 		 	UNIVERSITY OF TEXAS SYSTEM
					
	By:	 	 /s/ David J. Bachrach
	 		 	By:	 	 /s/ George Goldenberg

		 	David J. Bachrach	 		 		 	George Goldenberg
		 	Executive Vice President	 		 		 	President
		 	for Administration and Finance	 		 		 	
			
		 		 	BOARD OF REGENTS OF THE
	APPROVED AS TO CONTENT	 		 	UNIVERSITY OF TEXAS SYSTEM
					
	By:	 	 /s/ William Doty
	 		 	By:	 	 /s/ Michael E. Patrick

		 	William Doty	 		 		 	Michael E. Patrick
		 	Director, Technology Development	 		 		 	 Executive Vice Chancellor
 for Asset
Management

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Exhibit I 
 LICENSE AGREEMENT 
 THIS AGREEMENT is made by and between the Ohio State University Research Foundation
(“OSURF”) whose address is 1314 Kinnear Road, Columbus, Ohio 43212- 1194 and BOARD OF REGENTS (“BOARD”) OF THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th
Street, Austin, Texas 78701, and The University of Texas M.D. Anderson Cancer Center, a component Institution of the SYSTEM (“LICENSEE”). 
 WITNESSETH: 
 Whereas OSURF owns or controls certain Subject Patents which were developed at OSURF in part by Dr. [**], now an
employee of LICENSEE; 
 Whereas OSURF desires to have the Subject Patents developed and used for the benefit of LICENSEE, the inventor,
BOARD, and the public; and 
 Whereas LICENSEE wishes to obtain a license from OSURF to practice and sublicense for commercial development
the Subject Patents and any inventions made by Dr. Priebe or his co-workers that could only be practiced lawfully by LICENSEE or LICENSEE’s sublicensees with a license under one or more of the Subject Patents; 
 NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties hereto agree as follows: 
 I. 
 This agreement shall be effective as of
January 1, 1990 subject to approval by BOARD. 
 II. 
 OSURF grants to BOARD and LICENSEE a non-exclusive license under the Subject Patents for Dr. [**] and his co-workers to practice the inventions covered by such Subject Patents at LICENSEE for research purposes
only, including sponsored research, with the right to sublicense both research/development activities and commercial manufacture, use and/or sale under one or more of such Subject Patents to licensee(s) of any invention(s) made by Dr. [**] or
his coworkers at LICENSEE to the extent that such sublicense is reasonably required in order to develop and/or commercialize such invention(s) of Dr. [**] or coworkers, provided that LICENSEE will notify OSURF promptly of the granting of each
sublicense under the Subject Patents and will pay to OSURF a royalty of [**] of net sales, under a sublicense of Subject Patents granted by LICENSEE, of product(s) and/or service(s) covered by one or more of Subject Patents. OSURF makes no
representations or warranties of any kind with respect to Subject Patents or any results, products, processes, services or uses obtained, made, performed or used in accordance with their teachings. 
 III. 
 Any product manufactured, imported or
sold under authority of this license and covered by any claim of a Subject Patent will be marked with the number of each such patent. Neither LICENSEE nor any sublicensee(s) of LICENSEE under any Subject Patent(s) will use the name of OSURF in
connection with promotion or sale of any product(s) or service(s) the manufacture, import, sale or use of which is subject to this license agreement, except with the prior express written approval of OSURF. 
  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment
request. An unredacted version of this agreement has been filed separately with the Commission. 

 IV. 
 This license shall be effective upon Effective Date herein above. This license, and the accrual of sublicense royalties, shall terminate with respect to each of the Subject Patents upon the expiration of such patent. This license may also
be terminated by OSURF for material breach of its terms, including termination with respect to any sublicense for failure by LICENSEE to pay royalties owing to OSURF with respect to such sublicense within six (6) months of their accrual, upon
not less than two months written notice to LICENSEE specifying the grounds for termination, provided that such termination will not be effective if the breach is cured within one month after such notice. 
 V. 
 Subject patents are: 
 U.S. [**] issued [**]; 
 U.S. [**] issued
[**]; 
 U.S. [**] issued [**]; 
 U.S. [**] issued [**]; 
 IN WITNESS WHEREOF, parties hereto have caused their duly authorized representatives to execute three
(3) original counterparts of this AGREEMENT, each of which is of equal dignity. 
  

									
	THE UNIVERSITY OF TEXAS	 		 	OHIO STATE UNIVERSITY RESEARCH
	MD ANDERSON CANCER CENTER	 		 	FOUNDATION
					
	By:	 	 /s/ David J. Bachrach
	 		 	By:	 	 /s/ [Illegible] K. Meadow

		 	David J. Bachrach	 		 	Name:	 	
		 	Executive Vice President	 		 	Title:	 	
		 	for Administration and Finance	 		 		 	
				
	APPROVED AS TO CONTENT	 		 		 	
					
	By:	 	 /s/ William Doty
	 		 		 	
		 	William Doty	 		 		 	.
		 	Director, Technology Development	 		 		 	
				
	BOARD OF REGENTS OF THE	 		 		 	
	UNIVERSITY OF TEXAS SYSTEM	 		 		 	
					
	By:	 	 /s/ Michael E. Patrick
	 		 		 	
		 	Michael E. Patrick	 		 		 	
		 	Executive Vice Chancellor	 		 		 	
		 	for Asset Management	 		 		 	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Exhibit II 
 SUBLICENSE AGREEMENT 
 THIS AGREEMENT is made by and between the Ohio State University Research Foundation
(“OSURF”) whose address is 1314 Kinnear Road, Columbus, Ohio 43212- 1194 and BOARD OF REGENTS (“BOARD”) OF THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th
Street, Austin, Texas 78701, and The University of Texas M.D. Anderson Cancer Center, a component Institution of the SYSTEM (“SUBLICENSEE”). 
 WITNESSETH 
 Whereas OSURF is the exclusive licensee, under license agreements between OSURF and the United
States Department of Health and Human Services (“DHHS”), to certain Subject Patents which were developed at OSURF in part by Dr. Waldemar Priebe, now an employee of SUBLICENSEE; 
 Whereas OSURF desires to have the Subject Patents developed and used for the benefit of SUBLICENSEE, the inventor, BOARD, and the public; and 

Whereas SUBLICENSEE wishes to obtain a sublicense from OSURF to practice and sublicense for commercial development the Subject Patents and any
inventions made by Dr. [**] or his co-workers that could only be practiced lawfully by SUBLICENSEE or SUBLICENSEE’s sublicensees with a license under one or more of the Subject Patents; 
 NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties hereto agree as follows: 
 I. 
 This agreement shall be effective as
June 15, 1990, subject to approval by DHHS and BOARD. 
 II. 
 OSURF grants to BOARD and SUBLICENSEE a non-exclusive sublicense under the Subject Patents for Dr. [**] and his co-workers to practice the
inventions covered by such Subject Patents at SUBLICENSEE for research purposes only, including sponsored research, with the right to sublicense both research/development activities and commercial manufacture, use and/or sale under one or more of
such Subject Patents to licensee(s) of any invention(s) made by Dr. [**] or his co-workers at SUBLICENSEE to the extent that such sublicense is reasonably required in order to develop and/or commercialize such invention(s) of Dr. [**] or
co-workers, provided that SUBLICENSEE will notify OSURF promptly of the granting of each sublicense under the Subject Patents and will pay to OSURF a royalty of [**] percent [**] of net sales, under a sublicense of Subject Patents granted by BOARD,
of product(s) and/or service(s) covered by one or more of Subject Patents. OSURF makes no representations or warranties of any kind with respect to Subject Patents or any results, products, processes, services or uses obtained, made, performed or
used in accordance with their teachings. OSURF represents and warrants that it has the right to grant this sublicense pursuant to the terms hereof. 
  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with
the Commission. 

 III. 
 SUBLICENSEE agrees to use its reasonable best efforts to sublicense through BOARD the Subject Patents, for the purpose of commercial development of the Subject Patents, to Argus Pharmaceuticals, Inc., a corporation organized and doing
business under the laws of the State of Texas and having a place of business in The Woodlands, Texas. 
 IV. 
 Any product manufactured, imported or sold under authority of this license and covered by any claim of a Subject Patent will be marked with the number of
each such patent. Neither BOARD or SUBLICENSEE nor any sublicensee(s) of BOARD or SUBLICENSEE under any Subject Patent(s) will use the name of OSURF or DHHS in connection with promotion or sale of any product(s) or service(s) the manufacture,
import, sale or use of which is subject to this license agreement, except with the prior express written approval of OSURF. 
 V. 

This license shall be effective upon Effective Date herein above. This license, and the accrual of sublicense royalties, shall terminate with respect
to each of the Subject Patents upon the expiration of such patent. This license may also be terminated by OSURF for material breach of its terms, including termination with respect to any sublicense for failure by SUBLICENSEE to pay royalties owing
to OSIJRF with respect to such sublicense within six (6) months of their accrual, upon not less than two months written notice to SUBLICENSEE specifying the grounds for termination, provided that such termination will not be effective if the
breach is cured within one month after such notice. 
 VI. 
 Subject patents are: 
 U.S. [**] issued [**] 
 U.S. [**] issued [**] 
  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with
the Commission. 

 IN WITNESS WHEREOF, parties hereto have caused their duly authorized representatives to execute three
(3) original counterparts of this AGREEMENT, each of which is of equal dignity. 
  

									
	THE UNIVERSITY OF TEXAS	 		 	OHIO STATE UNIVERSITY RESEARCH
	MD ANDERSON CANCER CENTER	 		 	FOUNDATION
					
	By:	 	 /s/ David J. Bachrach
	 		 	By:	 	 /s/ John W. Tipka

		 	David J. Bachrach	 		 		 	John W. Tipka
		 	Executive Vice President	 		 		 	Acting Director
		 	for Administration and Finance	 		 		 	Sponsored Programs Administration
				
	APPROVED AS TO CONTENT	 		 		 	
					
	By:	 	 /s/ William Doty
	 		 		 	
		 	William Doty	 		 		 	.
		 	Director, Technology Development	 		 		 	
				
	BOARD OF REGENTS OF THE	 		 		 	
	UNIVERSITY OF TEXAS SYSTEM	 		 		 	
					
	By:	 	 /s/ Michael E. Patrick
	 		 		 	
		 	Michael E. Patrick	 		 		 	
		 	Executive Vice Chancellor	 		 		 	
		 	for Asset Management	 		 		 	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS 
 MD ANDERSON 
 CANCER CENTER 
 Legal Services (Internal) – 537 
 Corporate
Affairs 
 Intellectual Property 
 Risk Management 
 Telephone: (713) 794-4000 
 FAX (713) 799-8801 
 VIA FAX 
 February 10, 1993 
 Mr. David M. Leech 
 President and CEO 
 Argus Pharmaceuticals. Inc. 
 3400
Research Forest Drive 
 The Woodlands, Texas 77381 
 Dear
Mr. Leech: 
 Upon review of the present status of the Exclusive License Agreement dated July 1, 1988, between the Board of Regents of the
University of Texas System, The University of Texas M.D. Anderson Cancer Center, and Argus Pharmaceuticals, Inc., the issued United States patents, pending patent applications, and foreign patents and patent applications described in the schedule
attached hereto (dated February 8, 1993) are included in the Exclusive License Agreement. 
  

	
	 Sincerely,

	
	 /s/ Matthew Burr

	 Matthew Burr, J.D.

	 Internal Legal Services

	 Intellectual Property

	
	 Attachment

	
	 cc: William Doty

	 Cheryl McCants

	 Donna Gilberg

	 Dudley Dobie, Esq.

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D.ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. page 1 
  

													
	ID #: ACC: [**]	  	        [**]	  		  	Serial #: [**]	  	Filed: [**]	 		 	Status: ALD [**]
	 Parent 4’:
	  		  	Patent #’:	  	                Issued:	  		 	Last Action: FEE PAID [**]	 	
	AKA#:	  		  	Tax Date:	  		  		 		 	            Action 1:
	 Outside Counsel: KDG Their Ref: USTC:044
	  	                Federal Grant #: [**]	 	                            Action2:	 	
					
	 Assignee: University of Texas System
	  	Licensee: Argus	  		 		 	
	 Inventor1: [**]
	  	        Inventor2: [**].	  	Inventor3: [**]	  		 		 	
	 Inventor4:
	  		  		  	Inventor5:	  		 	Inventor6:	 	
	 Inventor7:
	  		  		  		  		 		 	
	Title: [**] (As Amended)	  		  		  		  		 		 	

  

															
	ID #: UTMDACC; [**]	  	[**]	  		  	            Serial #: [**]	  	Filed: [**]	  	Status: EXPIRES [**]
	Parent #:	  		  		  		  	Patent #: [**] Issued: [**]	  	            Last Action: NATIONAL [**]	  		 	
	AKA #	  		  		  		  		  	Tax Date: [**]	  		 	Action1:
	 Outside Counsel: KDG Their Ref: UTSC: 048
	  	Federal Grant #: [**]	  		  	Action2: WORKING [**]	 	
	 Assignee:
	  		  		  	Licensee: Argus	  		  		 	
	 Inventor1: [**]
	  		  	Inventor2: [**]	  		  	Inventor3: [**]	 	
	 Inventor4: [**]
	  	Inventor5:	  		  		  	            Inventor6:	  		 	
	 Inventor7:
	  		  		  		  		  		 	
	Title: [**]	  		  		  		  		  		  		 	

  

									
	ID #: UTHDACC: [**]	  	[**]	  	            Serial #: [**]	  	Filed: [**]	  	Status: PUBLISHED [**]
	Parent #:	  		  	Patent #:	  	Issued: Last Action	  	
	AKA#:	  		  		  	Tax Date:	  	Action1: REQ EXAM [**]
	 Outside Counsel; KDG Their Ref: UTSC:048
	  	Federal Grant #: [**]	  	Action2:	  	
	 Assignee: Licensee: Argus
	  		  		  	
	 Inventor1: [**]
	  	Inventor2: [**]	  	            Inventor3: [**]	  		  	
	 Inventor4: [**]
	  	Inventor5:	  		  	Inventor6:	  	
	 Inventor7;
	  		  		  		  	
	Title: [**]	  		  		  		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D.ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 2 
  

													
	ID #: UTHDACC: [**]	  	[**]	 		 	Serial #: [**]	 	            Filed: [**]	 		 	Status: EXPIRES [**]
	            Parent #:	  		 	Patent #: [**]	 		 	Issued: [**]	 	            Last Action:	 	
	AKA#:	  		 		 		 	            Tax Date: [**]	 		 	            Action1:
	            Outside Counsel: KUG Their Ref: UTSC:048	 	            Federal Grant #: [**]	 		 	            Action2:
	            Assignee:	  		 	Licensee: Argus	 		 		 		 	
	            Inventor1: [**]	  	.	 	Inventor2: [**]	 	.	 	Inventor3: [**]	 		 	
	            Inventor4: [**].	  		 		 	Inventor5:	 		 	Inventor6:	 	
	            Inventor7:	  		 		 		 		 		 	
	Title: [**]	  		 		 		 		 		 	
							
	ID #: UTHDACC: [**]	  	[**]	 		 	Serial #: [**]	 		 	Filed: [**]	 	Status: EXPIRES [**]
	            Parent #:	  		 	Patent #: [**]	 		 	Issued: [**]	 	            Last Action:	 	
	AKA#:	  		 		 		 	            Tax Date: [**]	 		 	            Action1:
	            Outside Counsel: KDG Their Ref: UTSC:053	 	                            Federal Grant #:	 		 	                        Action2:
	            Assignee:	  		 	Licensee: Argus	 		 		 		 	
	            Inventor1: [**]	  	Inventor2: [**]	 	            Inventor3: [**]	 		 		 	
	            Inventor4:	  		 		 	            Inventor5:	 		 	            Inventor6:	 	
	            Inventor1:	  		 		 		 		 		 	
	Title: [**]	  		 		 		 		 		 	
							
	ID #: UTHDACC: [**]	  	[**]	 		 	Serial #: [**]	 	            Filed: [**]	 		 	Status: PUBLISHED
	            Parent #:	  		 	Patent#: [**]	 		 	Issued: [**]	 	Last Action: FEE PAID [**]
		  		 		 		 	            Tax Date: [**]	 		 	            Action1:
	            Outside Counsel: KDG Their Ref: UTSC:053	 	                            Federal Grant #:	 		 	                        Action2:
	            Assignee:	  		 	Licensee: Argus	 		 		 		 	
	            Inventor1 [**].	  		 	Inventor2: [**]	 	                            Inventor3: [**]	 		 	
	            Inventor4:	  		 		 	            Inventor5:	 		 	                            Inventor6:
	            Inventor7:	  		 		 		 		 		 	
	Title: [**]	  		 		 		 		 		 	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D.ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 3 
  

													
	ID I: UTMDACC: [**]	  	[**]	  		  	Serial #: [**]	  		  	Filed: [**]	  	Status: PENDING
	Parent #I:	  		  	Patent #:	  	Issued:	  		  	Last Action:	  	
	AKA#:	  		  	Tax Date:	  		  		  	Action1: REQ EXAM [**]
	Outside Counsel: KDG	  	Their Ref: UTSC:053                        	  		  	Federal Grant #:	  	Action2:
	Assignee:	  		  	Licensee: Argus	  		  		  		  	
	Inventor1: [**]	  		  	Inventor2: [**]	  		  	 Inventor3: [**]
	  	
	Inventor4:	  		  	Inventor5:	  		  	 Inventor6:
	  	
	Inventor7:	  		  		  		  		  		  	
							
	Title: [**]	  		  		  		  		  		  	
							
	ID: UTMDACC: [**]	  	[**].	  	Serial # [**]	  		  		  	Filed: [**]	  	Status: EXPIRES [**]
	Parent #:	  		  	Patent #: [**]	  	Issued: [**]	  		  	Last Action:	  	
		  		  	Tax Date: [**]	  		  		  	Action1:	  	
	Outside Counsel: KDG	  	Their Ref: UTSC: 053                        
	  		  	Federal Grant #:	  	Action2:
	Assignee:	  		  	Licensee: Argus	  		  		  		  	
	Inventor1: [**]	  		  	Inventor2: [**] .	  		  	 Inventor3: [**]
	  	
	Inventor4:	  	.	  	Inventor5:	  		  	 Inventor6:
	  	
	Inventor7:	  		  		  		  		  	
							
	Title: [**]	  		  		  		  		  		  	
		  		  		  		  		  		  	
	ID #: UTMDACC: [**]	  	[**]	  	Serial #: [**]	  		  		  	Filed: [**]	  	Status: EXPIRES [**]
	Parent #	  		  	Patent #: [**]	  	Issued:	  		  		  	Last Action:
	AKA#:	  		  	Tax Date: [**]	  		  		  		  	Action1:
	Outside Counsel: KDG	  	Their Ref: UTSC:054	  	Federal Grant #: [**]	  		  	Action2:
	Assignee:	  		  	Licensee: Argus	  		  		  		  	
	Inventor1: [**].	  		  	Inventor2:	  		  	 Inventor3:
	  	
	Inventor4:	  		  	Inventor5:	  		  	 Inventor6:]
	  	
	Inventor7:	  		  		  		  		  		  	
	Title: [**]	  		  		  		  		  		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D.ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 4 
  

													
	ID #: UTHDACC: [**]	  	[**]	  	        Serial #: [**]	  	                          Filed: [**]	  	Status: EXPIRES [**]
	Parent #:	  		  	Patent #: [**]	  	            Issued: [**]         Last Action:	  	
	AKA#:	  		  		  	                          Tax Date: [**]	  	                Action1:
	 Outside Counsel: KDG Their Ref: UTSC:054
	  	Federal Grant #: [**]	  	Action2; WORKING [**]
	 Assignee:
	  		  	Licensee: Argus	  		  		 		  	
	 Inventor1: [**]
	  	Inventor2:	  		  	Inventor3:	  		 		  	
	 Inventor4:
	  		  	                            Inventor5:
	  	Inventor6:	 		  	
	 Inventor7:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	
					
	ID #: UTHDACC: [**]	  	[**]	  	        Serial #: [**]	  	                          Filed: [**]        	  	Status: PENDING
	Parent #:	  		  	Patent #:	  	                          Issued: Last Action:	  	
	AKA#:	  		  		  	                          Tax Date:	  	Action1: RfX2 EXAM [**]
	 Outside Counsel: KDG Their Ref: UTSC:054
	  	Federal Grant #: [**]	 		  	                Action2:
	 Assignee:
	  		  	Licensee: Argus	  		  		 		  	
	 Inventor1: [**].
	  		  	Inventor2:	  	Inventor3:	  		 		  	
	 Inventor4:
	  		  	                            Inventor5:
	  	Inventor6:	 		  	
	 Inventor7:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	
					
	ID #: UTHDACC: [**]	  	[**]	  	        Serial #: [**]	  	                          Filed: [**]	  	Status: EXPIRES [**]
	Parent #:	  		  	Patent #: [**]	  	            Issued: [**] Last Action:	  	
		  		  		  	                          Tax Date:
[**]	  	                Action1:
	 Outside Counsel: KX Their Ref: UTSC:054
	  	Federal Grant #: [**]	 		  	Action2:
	 Assignee:
	  		  	Licensee: Argus	  		  		 		  	
	 Inventor1: [**].
	  		  	Inventor2:	  	Inventor3:	  		 		  	
	 Inventor4:
	  		  	                            Inventor5:
	  	Inventor6:	 		  	
	 Inventor7:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D.ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 5 
  

									
	ID #; UTHDACC: [**]	  	[**]	  	Serial #: [**]	  	                Filed: [**]	  	                    Status: EXPIRES [**]
	Parent #:	  		  	Patent #: [**]	  	                Issued: Last Action:	  	
		  		  		  	                            Tax Date: [**]	  	                                Action1:
	 Outside Counsel: KDG Their Ref: UTSC:056
	  	Federal Grant #: [**]	  	    Action2: REQ EXAM [**]
	 Assignee:
	  		  	Licensee: Argus	  		  	
	 Inventor1: [**]
	  		  	Inventor2: [**]	  	Inventor3: [**]	  	
	 Inventor4: [**]
	  	Inventor5:	  	                Inventor6:	  	
	 Inventor7:
	  		  		  		  	
	Title: [**]	  		  		  		  	
				
	ID #; UTHDACC: [**]	  	Serial #: [**]	  	Filed: [**]	  	                Status: PUBLISHED [**]
	Parent #:	  		  	Patent #: [**]	  	                Issued: Last Action: RESPOND OA [**]
		  		  		  	                            Tax Date:
[**]	  	                                Action1:
	 Outside Counsel: KDG Their Ref; UTSC:056
	  	Federal Grant #: [**]	  	Action2:
	 Assignee:
	  		  	Licensee: Argus	  	
	 Inventorl: [**]
	  		  	Inventor2; [**]	  	                Inventor3: [**]	  	
	 Inventor4: [**
	  		  	Inventor5;	  	                            Inventor6:	  	
	 Inventor7:
	  		  		  		  	
	Title: [**]	  		  		  		  	
					
	ID #: UTHDACC: [**]	  	[**]	  	     Serial #: [**]
	  	                            Filed: [**]	  	                Status: PENDING
	Parent #:	  		  	Patent #:	  	                            Issued:
Last Action:
	AKA#:	  		  		  	                            Tax Date;	  	                            Action1: REQ
EXAM [**]
	 Outside Counsel: KDG Their Ref: UTSC:056         F
	  	Federal Grant #: [**]	  	Action2:
	 Assignee:
	  		  	Licensee: Argus	  	
	 Inventor1: [**]
	  		  	Inventor2; [**]	  	Inventor3: [**]	  	
	 Inventor4: [**]
	  	Inventor5:	  	                Inventor6:	  	
	 Inventor7:
	  		  		  		  	
	Title: [**]	  		  		  		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS ANDERSON CANCER CENTER 
 2/08/ 93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 6 
  

													
	ID #: UTHDACC; [**]	  	[**]	  	            Serial #: [**]	  	                          Filed: [**]	  	Status: EXPIRES [**]
	Parent #:	  		  	Patent #: [**]	  	            Issued: [**] Last Action:	  	
	AKA#:	  		  		  	                          Tax Date:
[**]	  	Action1:
	 Outside Counsel: KDG Their Ref: UTSC:056
	  	Federal Grant #: [**]	 	Action2:	  	
	 Assignee:
	  	                    Licensee: Argus	  		 		  	
	 Inventor1: [**]
	  		  	Inventor2: [**]	  	            Inventor3:	  	[**]	 		  	
	 Inventor4: [**]
	  		  	Inventor5:	  	Inventor6:	  		 		  	
	 Inventor7:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	
					
	ID #: UTMBACC: [**]	  	[**]	  	            Serial #: [**]	  	Filed: [**]	 	            Status: EXPIRES [**]
	Parent #:	  		  	            Patent #: [**]	  	Issued: [**]	 	            Last Action:
	AKA#:	  		  		  		  	Tax Date: [**]	 		  	Action1: WORKING [**]
	Outside Counsel: KDG Their Ref: UTSC:061 Federal Grant If:	  		 		  	                Action2:
	 Assignee:
	  	                    Licensee: Argus	  		 		  	
	 Inventor1: [**]
	  		  	            Inventor2: [**]	  		  	Inventor3:	 		  	
	 Inventor4:
	  	Inventor5:	  	Inventor6:	  		  		 		  	
	 Inventor7:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	
					
	ID #: UTMDACC: [**]	  	[**]	  	Serial #: [**]	  	                          Filed: [**]	  	Status: EXPIRES [**]
	Parent #:	  		  	Patent #: [**]	  	            Issued: Last Action: NATIONAL [**])	  	
		  		  		  	                          Tax Date: [**]	  	Action1: WORKING [**]
	 Outside Counsel: XDG Their Ref: UTSC:061 Federal Grant #:
	 		  	                Action2:
	 Assignee:
	  	                    Licensee: Argus	  		 		  	
	 Inventor1: [**]
	  		  	            Inventor2: [**]	  		  	Inventor3:	 		  	
	 Inventor4:
	  	Inventor5:	  	Inventor6:	  		  		 		  	
	 Inventor1:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D.ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 7 
  

													
	ID #: UTMDACC: [**]	  	[**]	  	                            Serial #:
[**]	  	Filed: [**]	 		  	Status:
	PENDING	  		  		  		  		 		  	
	Parent #:	  		  	Patent #: Issued: Last Action:	  		 		  	
	AKA#:	  		  		  	                Tax Date:	 		  	Action1: REQ EXAM [**]
	 Outside Counsel: KDG Their Ref: UTSC:061
	  	Federal Grant #:	 		  	                Action2:
	 Assignee:
	  		  	Licensee: Argus	  		  		 		  	
	 Inventor1: [[**]
	  		  	Inventor2: [**]    Inventor3:	  		 		  	
	 Inventor4:
	  		  	            Inventor5:	  		  		 	Inventor6:	  	
	 Inventor1:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	
						
	ID #: UTMDACC: [**] [**]        	  		  	Serial #: [**]	  	Filed: [**]	 		  	Status: EXPIRES [**]
	Parent #:	  		  	Patent I: [**]	  	Issued: [**] Last Action:	 		  	
	AKA#:	  		  		  	                Tax Date: [**]	 		  	Action1:
	 Outside Counsel: KDG Their Ref: UTSC:061
	  	Federal Grant #:	 		  	                Action2:
	 Assignee:
	  		  	Licensee: Argus	  		  		 		  	
	 Inventor1: [**]
	  		  	Inventor2: [**]	  		  	Inventor3:	 		  	
	 Inventor4:
	  		  	            Inventor5:	  		  		 	Inventor6:	  	
	 Inventor1:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	
					
	ID #: UTMDACC: [**]	  	[**]	  	            Serial #: [**]	  	                Filed: [**]	 	                                    Status:
EXPIRES
	Parent #:	  		  	Patent #: [**]	  	Issued: [**] Last Action:	 		  	
		  		  		  	                Tax Date: [**]	  	Action1:
	 Outside Counsel: KDG Their Ref: UTSC:062
	  	Federal Grant #:	 		  	Action2: WORKING [**]
	 Assignee:
	  		  	Licensee: Argus	  		  		 		  	
	 Inventor1: [**]
	  	Inventor2: [**]	  	                            Inventor3:
[**]	 		  	
	 Inventor4:
	  		  	            Inventor5:	  		  		 	Inventor6:	  	
	 Inventor7:
	  		  		  		  		 		  	
	Title: [**]	  		  		  		  		 		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 8 
  

																	
	ID #: UTMDACC: [**]                [**]	  	Serial #: [**]	  		  	Filed: [**]	  		  	Status: EXPIRES
	Parent #:	  	Patent #: [**]	  	 Issued: [**]
	  	Last Action:
		  	Tax Date: [**]	  		  		  		  	Action1:
		  	Outside Counsel: KDG Their Ref: UTSC:062 Federal Grant #:	  		  	Federal Grant #: [**]	  		  	Action2:
		  	Assignee:	  		  	Licensee: Argus	  		  		  		  	
		  	Inventor1: [**]	  	Inventor2: [**]  Inventor3: [**]	  		  		  		  	
		  	Inventor4:	  		  	Inventor5:	  		  	Inventor6:	  		  	
		  	Inventor7:	  		  		  		  		  		  	
						
	Title: [**]	  		  		  		  		  	

  

																	
						
	ID #: UTMDACC: [**]                [**]	  	Serial #: [**]	  		  	Filed: [**]	  		  	Status: EXPIRES [**]
	Parent #:	  		  	Patent #: [**] Issued:	  	 Last Action
	  	:
	AXA#	  	Date:	  		  		  		  	Action1:
		  	Outside Counsel: KDG Their Ref: UTSC:064	  		  		  	Federal Grant #:	  		  	Action2: WORKING [**]
		  	Assignee:	  		  		  	Licensee: Argus	  		  		  	
		  	Inventor1: [**]  Inventor2: [**]	  	Inventor3:	  		  	
		  	Inventor4:	  		  		  	Inventor5:	  		  	Inventor6:	  		  	
		  	Inventor7:	  		  		  		  		  		  		  	
						
	Title: [**]	  		  		  		  		  	

  

																	
						
	ID #: UTMDACC: [**]                [**]	  	Serial #: [**]	  		  	Filed: [**]	  		  	Status: PENDING
	Parent #:	  		  	Patent #:	  	Issued:	  		  	Last Action:
	AKA#1:	  	Tax Date:	  		  		  		  	Action1: REQ EXAM [**]
		  	Outside Counsel: KDG Their Ref: UTSC: 064	  	Federal Grant #:	  		  	Action2:
		  	Assignee:	  	Licensee: Argus	  		  		  	
		  	Inventor1: [**]                Inventor2: [**]	  	Inventor3:
		  	Inventor4:	  	Inventor5:	  		  		  		  	Inventor6:
		  	Inventor7:	  		  		  		  		  	
						
	Title: [**]	  		  		  		  		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 9 
  

													
	 ID #: UTMDACC: [**]
	  	[**]        CON	  		  	Serial #: [**]	  	 Filed: [**]
	  	Status: EXPIRES [**]
	Parent #: [**]	  	[**]                	  		  	Patent #: [**]	  	 Issued: [**] Last Action:
	  	
	AKA#:	  		  	Tax Date: [**]	  		  		  		  	Action1:
	 Outside Counsel: FOG Their Ref: UTSC:150 Federal Grant if: Action2:

	 Assignee: Licensee: Argus

	 Inventor1: [**]
	  		  	Inventor2: [**]	  		  	Inventor3:	  	
	 Inventor4:
	  		  	Inventor5:	  		  		  	Inventor6:	  	
	 Inventor7:
	  		  		  		  		  		  	
	Title: [**]	  		  		  		  		  		  	

  

													
	ID #: UTMDACC: [**]	  	 [**]        
	  	 Serial #: [**]
	  	 Filed: [**]
	  	Status: PENDING	  		  	
	Parent /1:	  	 Patent #:
	  	 Issued:
	  	 Last Action:
	  	         RESPOND OA [**]
	  	
	AKA#: IDR9O-018	  		  	 Tax Date:
	  		  		  		  	Action1:
	 Outside Counsel: KDG Their Ref: UTSC:190        Federal Grant #:
	  	 Action2: NATIONAL [**]

	 Assignee: University of Texas/Argus
	  	 Licensee: Argus
	  		  		  		  	
	 Inventor1: [**]
	  	Inventor2: [**]	  	Inventor3: [**]	  		  	
	 Inventor4:
	  	 Inventor5:
	  		  	Inventor6:	  		  	
	 Inventor7:
	  		  		  		  		  	
	 Title: [**]
	  		  		  		  		  		  	

  

													
	 ID #: UTMDACC[**]
	  	 [**]        
	  	 Serial #: [**]
	  	 Filed: [**]
	  		 	Status: EXPIRES [**]
	 Parent #:
	  		  	 Patent #: [**]
	  	 Issued: [**]
	  	Last Action:	  	
	 AKA#: IDR9O-018
	  		  	 Tax Date:[**]
	  		  		 	Action1:	  	
	 Outside Counsel: KDG Their Ref: UTSC:190        Federal Grant #:
	  		 	Action2:	  	
	 Assignee: University of Texas/Argus Licensee: Argus
	  	
	 Inventor1: [**]
	  	 Inventor2: [**]
	  	 Inventor3: [**]
	  		 		  	
	 Inventor4:
	  	 Inventor5:
	  		  	Inventor6:	 		  	
	 Inventor7:
	  		  		  		 		  	
	 Title: [**]
	  		  		  		  		 		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF T(AS ANDERSON CANCER CENTER 
 2/08/93 ‘PATENTS/APPLICATIONS LICENSED iv ARGUS PHARMACEUTICALS, INC. Page 10 
  

																	
	ID #: UTMDACC: [**]                 [**]	  	Serial #: [**]	  		  	Filed: [**]	  		  	Status: PENDING
	Parent #: [**] [**]	  		  	Patent #: Issued:	  	 Last Action: RESPOND OA [**]
	  	
	AKA#: IDR9O-017	  	Tax Date:	  		  		  		  	Action1:
		  	Outside Counsel: KDG Their Ref: UTSC:191	  	Federal Grant #: [**]	  		  	Action2: NATIONAL [**]
		  	Assignee: University of Texas System/NIH	  	Licensee: Argus/Squibb+	  		  		  		  	
		  	Inventor1: [**] Inventor2: [**]	  	Inventor3: [**]	  		  		  		  	
		  	Inventor4:	  	Inventor5:	  		  	Inventor6:	  		  	
		  	Inventor7:	  		  		  		  		  	
						
	Title: [**]	  		  		  		  		  	
						
	ID #: UTMDACC: [**]                [**]	  	Serial #: [**]	  		  	Filed: [**]	  		  	Status: PUBLISHED [**]
	Parent #:	  		  	Patent #:	  	Issued Last:	  		  		  	Action: RESPOND WO [**]
	AKA#: IDR9O-030	  	Tax Date:	  		  		  		  	Action1:
		  	Outside Counsel: KDG Their Ref: UTSC:208	  	Federal Grant #: [**]	  		  	Action2: NATIONAL [**]
		  	Assignee: University of Texas System	  	Licensee: Argus	  		  		  	
		  	Inventor1: [**]  Inventor2: [**]	  		  	Inventor3: [**]	  		  		  		  	
		  	Inventor4:	  		  	Inventor5:	  		  	Inventor6:	  		  	
		  	Inveritor7:	  		  		  		  		  		  	
	Title: [**]	  		  		  		  		  	
						
	ID #: UTMDACC [**]                [**]	  	Serial #: [**]	  		  	Filed: [**]	  		  	Status: PENDING
	Parent #: [**] [**]	  		  	Patent #: Issued:	  	 Last Action:
	  		  		  	
		  	Tax Date:	  		  		  		  	Action1: CHII [**]
		  	Outside Counsel: KDG Their Ref: UTSC:246	  	Federal Grant #: [**]	  		  	Action2: NATIONAL [**]
		  	Assignee: University of Texas/Argus	  	Licensee: Argus	  		  		  	
		  	Inventor1: [**]	  	Inventor2: [**]	  		  	Inventor3: [**]
		  	Inventor4: [**]	  	Inventor5: [**]	  		  	Inventor6:	  		  	
		  	Inventor7;	  		  		  		  		  	
						
	Title: [**]	  		  		  		  		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED TO ARGUS PHARMACEUTICALS, INC. Page 11 
  

														
	ID #: UTMDACC: [**]	  	[**]	  	CIP	  		  	Serial #: [**]	  	Filed: [**]            	 	 	Status: PENDING
	Parent II: [**] [**]	  	Patent #:	  		  	Issued: Last Action: FORG FILE [**]	 	 	
	AKAI:	  		  	Tax Date:	  		  		  			 	Action1:
	Outside Counsel: KDG Their Ref: UTSC:246	  	Federal Grant #:	  		  		  			 	Action2:
	 Assignee: University of Texas/Argus
	  	Licensee: Argus	  		  		  			 	
	 Inventor1: [**]
	  		  	Inventor2: [**]	  		  		  	Inventor3:	[**]	 	
	 Inventor4: [**]
	  		  	Inventor5: [**]	  		  	Inventor6:	  			 	
	 Inventor7:
	  		  		  		  		  			 	
	Title: [**]	  		  		  		  		  			 	

  

											
	ID #: UTMDACC: [**]	  	[**]	  	CON	  	Serial #: [**]	  	Filed: [**]	 	Status: PENDING
	Parent #; [**] [**]	  		  	Patent #/: Issued:	  	Last Action:	  		 	
	AXA#:	  		  	Tax Date:	  		  		 	Action#: RESP OA [**]
	Outside Counsel: KDG Their Ref: UTSC:301	  		  		  	Federal Grant #: [**]	  		 	Action2:
	 Assignee: University of Texas System/NIH
	  		  		  	Licensee: Argus/Squibb+	  		 	
	 Inventorl: [**]
	  		  	Inventor2: [**]	  		  	Inventor3: [**]	 	
	 Inventor4:
	  	Inventor5:	  	Inventor6:	  		  		 	
	 Inventorl:
	  		  		  		  		 	
	Title:[**]	  		  		  		  		 	

  

												
	ID #: UTMDACC: [**]	  	[**]	  	CON	  	Serial #: [**]	  	Filed: [**]	 	 	Status: PENDING
	Parent #: [**] [**]	  		  	Patent #: Issued:	  	Last Action: RESPOND OA [**]	  			 	
	AKA#:	  		  	Tax Date:	  		  			 	Action1:
	 Outside Counsel: KDG Their Ref: UTSC:302
	  	Federal Grant #:	  		  			 	Action2:
	 Assignee: University of Texas/Argus
	  		  	Licensee: Argus	  		  			 	
	 Inventor1: [**]
	  		  	Inventor2: [**]	  		  	Inventor3: 	[**]	 	
	 Inventor4:
	  		  	Inventor5:	  		  	Inventor6:	 	 	
	 Inventor7:
	  		  		  		  			 	
	Title: [**]	  		  		  		  			 	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 - THE UNIVERSITY OF TEXAS ANDERSON CANCER CENTER 
 2/08/93 PATENTS/APPLICATIONS LICENSED O ARGUS PHARMACEUTICALS, INC. Page 12 
  

									
	 ID #: UTMDACC: [**]
	  	[**]	  	Serial #: [**]	  	Filed[**]	  	Status: PENDING
	 Parent #: [**] [**]
	  	Patent #: Issued:	  	Last Action: RESPOND OA [**]	  	
		  	 Tax Date:
	  		  		  	Action1:
	 Outside Counsel: DLN Their Ref: UTSC:306
	  	Federal Grant #: [**]	  		  	Action2: FORG FILE [**]
	 Assignee: University of Texas System
	  	Licensee: Argus	  		  	
	 Inventor1: [**]
	  	Inventor2: [**]	  	Inventor3: [**]	  		  	
	 Inventor4:
	  	Inventor5:	  		  	Inventor6:	  	
	 Inventor1:
	  		  		  		  	
	 Title: [**]
	  		  		  		  	

									
					
	 ID #: UTMDACC: [**]
	  	[**]	  	Serial #:	  	Filed: [**]	  	Status: FILED
	 Parent #:
	  		  	Patent #: Issued:	  	Last Action:	  	
	 AKA#: 1DR93:015
	  		  	Tax Date:	  		  	Action1:
	 Outside Counsel: KDG Their Ref: UTSC;332
	  	Federal Grant #:	  		  	Action2:
	 Assignee:
	  	Licensee: Argus	  		  	
	 Inventor1: [**]
	  	Inventor2: [**]	  	Inventor3: [**]	  		  	
	 Inventor4:
	  	Inventor5:	  	Inventor6:
	 Inventor7:
	  		  		  		  	
	 Title:[**]
	  		  		  		  	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Patents Sublicensed to Argus Pharmaceuticals, Inc. Subject to Agreements Between The University of Texas M.D. Anderson
Cancer Center and Ohio State University Research Foundation: 
  

	1.	[**] U.S. Patent [**], Filed [**]. 

  

	2.	[**], U.S. Patent No. [**], Filed [**]. 

  

	3.	[**], U.S. Patent No. [**]. Filed [**]. 

  

	4.	[**], U.S. Patent No. [**]. Filed [**]. 

  

	5.	[**], U.S. Patent No. [**]. Filed [**]. 

  

	6.	[**], U.S. Patent No. [**]. Filed [**]. 

  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with
the Commission. 

 AMENDMENT NO. 3 
 TO THE 
 EXCLUSIVE LICENSE AGREEMENT 
 This is AMENDMENT NO. 3, effective this 9 day of December, 1993 (“Effective Date”), to the Exclusive License Agreement dated the first day of
July, 1988 (hereinafter referred to as the “Agreement”), between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as “UTMDACC”), located at Houston, Texas, and which is a component institution of THE
UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as “SYSTEM”) which is governed by a BOARD OF REGENTS (hereinafter referred to as “BOARD”) and Argus Pharmaceuticals Inc., located at 3400 Research Forest Drive, The Woodlands,
Texas, 77381 (hereinafter referred to as “Argus”). 
 RECITATIONS 
  

	A.	BOARD is the owner of the patent and technology rights of the U.S. Patent Application entitled “[**], SN
                    , invented by [**], filed [**], (UTMDACC Ref: [**]) (the “Invention”), developed at the UTMDACC, which Invention
relates to formulations of liposomal methyiphosphonate oligonucleotides and their use in the treatment of cancer. 

  

	B.	Argus is a pharmaceutical company interested in the development and commercialization of lipophilic compounds with medicinal potential, to which end Argus and UTMDACC entered into a
Research and Development Contract (“R&D Contract”) which is incorporated into the Agreement, and Argus wishes to obtain exclusive rights to the Invention. 

  

	C.	BOARD wishes to grant Argus exclusive rights to the Invention to promote its practical development for the benefit of the UTMDACC’s patients and for the benefit of the people
of the state of Texas. 

  

	D.	The Invention is “Related Technology” under the Agreement (although Argus funding in support of the research resulting in the Invention is attributable to the
Discretionary Account provided under the R&D Contract); therefore the Invention is licensed to Argus under this Amendment No. 3 to the Agreement. 

  

	E.	The Agreement, Amendment No. 1, and Amendment No. 2 thereto are not otherwise modified except as set forth in this Amendment No. 3. The definitions set forth in the
Agreement, Amendment No. 1, and Amendment No. 2 shall apply in this Amendment No. 3 except to the extent that a definition herein is specific to this Amendment No. 3. 

  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment
request. An unredacted version of this agreement has been filed separately with the Commission. 

 Amendment No. 3 
 Page 2

 NOW, THEREFORE, in consideration for the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the parties hereby agree to
the following: 
 1. The Agreement is amended to include within the Grant of Rights at Article II (A) BOARD’S rights in the Invention and information or
discoveries covered by patents and/or patent applications relating thereto, whether domestic or foreign, and all divisionals, continuations, reissues, reexaminations or extensions thereof, and any letters patent that issue thereon. The Grant of
Rights shall also include BOARD’s undivided interest in any patent applications that may be filed, or patents issuing therefrom, owned jointly by Argus and BOARD relating to the invention. 
 2. Argus shall pay UTMDACC the royalties specified in the Agreement on Net Sales of Products from the Invention, the same as if the Invention had been originally
included in the Agreement, and the royalties shall not be reduced in the event of joint invention or ownership by Argus and UTMDACC or BOARD of any subsequent patent applications or patents related to the Invention. 
 3. Argus shall reimburse UTMDACC for all outstanding (unreimbursed) patent expenses related to the Invention as of the Effective Date of this Amendment No. 3. Argus
shall further reimburse UTMDACC for all continuing patent expenses for the Invention for the term of this Amendment No. 3, pursuant to invoicing by UTMDACC. 
 4. Argus shall use reasonable best efforts to diligently commercialize the Inventions and obtain all required legal and regulatory approvals for Products from the Inventions. 
 5. The UTMDACC shall have the first option, subject to its own internal review and approval, to perform clinical trials of Products from the Inventions, and to perform other appropriate research on the Inventions that
is not conducted by Argus itself. 
  
 [**] = Portions of this agreement have been
omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Amendment No. 3 
 Page 3

 OTHERWISE, the terms and provisions of the original Agreement, Amendment No. 1 and Amendment No. 2 thereto shall remain in full
force and effect, provided, however, that in the event of a conflict in the terms and conditions between this Amendment No. 3 and the License Agreement, the terms and conditions of this Amendment shall prevail. 
 IN WITNESS WHEREOF, the parties have executed three (3) original counterparts of this Amendment No. 3, each of which is of equal dignity and
effective as of the date first hereinabove written. 
  

									
	 THE UNIVERSITY OF TEXAS
 M.D. ANDERSON CANCER
CENTER
	 		 	 BOARD OF REGENTS OF THE
 UNIVERSITY OF
TEXAS SYSTEM

					
	By:	 	 /s/ David J. Bachrach
	 		 	By:	 	 /s/ Ray Farabee

		 	David J. Bachrach	 		 		 	Ray Farabee
		 	Executive Vice President For Administration and Finance	 		 		 	Vice Chancellor and General Counsel
				
	APPROVED AS TO CONTENT	 		 		 	
					
	By:	 	 /s/ William J. Doty
	 		 	By:	 	 /s/ Dudley R. Dobie, Jr.

		 	William J. Doty	 		 		 	Dudley R. Dobie, Jr.
		 	Director, Technology Development	 		 		 	Manager, Intellectual Property
				
	Argus Pharmaceuticals, Inc.	 		 		 	
					
	By:	 	 /s/ David Leech
	 		 		 	
		 	David Leech	 		 		 	
		 	President	 		 		 	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 AMENDMENT NO. 5 
 TO THE 
 EXCLUSIVE LICENSE AGREEMENT 
 This is AMENDMENT NO. 5, effective this 9th day of August, 1994 (“Effective Date”), to the Exclusive License Agreement dated the
first day of July, 1988 (hereinafter referred to as the “Agreement”), between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as “UTMDACC”), located at Houston, Texas, and which is a component
institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as “SYSTEM”) which is governed by a BOARD OF REGENTS (hereinafter referred to as “BOARD”) and Argus Pharmaceuticals Inc., located at 3400 Research Forest
Drive, The Woodlands, Texas, 77381 (hereinafter referred to as “Argus”). 
 RECITATIONS 
  

	A.	BOARD is the owner of the patent and technology rights of the invention entitled [**] invented by Dr. [**] (UTMDACC Ref: UTSC: [**]) (the “Invention”), developed at
the UTMDACC, which Invention relates to the novel composition and method of preparing preliposome lyophilizates and their use in improving the characteristics of liposomal suspensions. 

  

	B.	Argus is a pharmaceutical company interested in the development and commercialization of lipophilic compounds with medicinal potential, to which end Argus and UTMDACC entered into a
Research and Development Contract (“R&D Contract”) which is incorporated into the Agreement, and Argus wishes to obtain exclusive rights to the Invention. 

  

	C.	BOARD wishes to grant Argus exclusive rights to the Invention to promote its practical development for the benefit of the UTMDACC’s patients and for the benefit of the people
of the state of Texas. 

  

	D.	The Invention is “Related Technology” under the Agreement (although Argus funding in support of the research resulting in the Invention is attributable to the
Discretionary Account provided under the R&D Contract); therefore the Invention is licensed to Argus under this Amendment No. 4 to the Agreement. 

  

 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed
separately with the Commission. 

 Amendment No. 5 
 Page 2

  

	E.	The Agreement, Amendment No. 1, Amendment No. 2, Amendment No. 3, thereto are not otherwise modified except as set forth in this Amendment No. 4. The definitions
set forth in the Agreement, Amendment No. 1, Amendment No. 2 , and Amendment No. 3, shall apply in this Amendment No. 5 except to the extent that a definition herein is specific to this Amendment No. 5.

 NOW, THEREFORE, in consideration for the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the parties
hereby agree to the following: 
  

	1.	The Agreement is amended to include within the Grant of Rights at Article II (A) BOARD’S rights in the Invention and information or discoveries covered by patents and/or
patent applications relating thereto, whether domestic or foreign, and all divisionals, continuations, reissues, reexaminations or extensions thereof, and any letters patent that issue thereon. The Grant of Rights shall also include BOAR D’s
undivided interest in any patent applications that may be filed, or patents issuing therefrom, owned jointly by Argus and BOARD relating to the invention. 

  

	2.	Argus shall pay UTMDACC the royalties specified in the Agreement on Net Sales of Products from the Invention, the same as if the Invention had been originally included in the
Agreement, and the royalties shall not be reduced in the event of joint invention or ownership by Argus and UTMDACC or BOARD of any subsequent patent applications or patents related to the Invention. 

  

	3.	Argus shall reimburse UTMDACC for all outstanding (unreimbursed) patent expenses related to the Invention as of the Effective Date of this Amendment No. 5. Argus shall further
reimburse UTMDACC for all continuing patent expenses for the Invention for the term of this Amendment No. 5, pursuant to invoicing by UTMDACC. 

  

	4.	Argus shall use reasonable best efforts to diligently commercialize the Inventions and obtain all required legal and regulatory approvals for Products from the Inventions.

  

	5.	The UTMDACC shall have the first option, subject to its own internal review and approval, to perform clinical trials of Products from the Inventions, and to perform other
appropriate research on the Inventions that is not conducted by Argus itself. 

  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Amendment No. 5 
 Page 3

 OTHERWISE, the terms and provisions of the original Agreement, Amendment No. 1, Amendment No. 2 and Amendment No. 3,
thereto shall remain in full force and effect, provided, however, that in the event of a conflict in the terms and conditions between this Amendment No. 5 and the License Agreement, the terms and conditions of this Amendment shall prevail.

 IN WITNESS WHEREOF, the parties have executed three (3) original counterparts of this Amendment No. 5, each of which is of equal
dignity and effective as of the date first hereinabove written. 
  

									
	 THE UNIVERSITY OF TEXAS
 MD ANDERSON CANCER
CENTER
	 		 	 BOARD OF REGENTS OF THE
 UNIVERSITY OF
TEXAS SYSTEM

					
	By:	 	 /s/ David J. Bachrach
	 		 	By:	 	 /s/ Ray Farabee

		 	David J. Bachrach	 		 		 	Ray Farabee
		 	Executive Vice President for Administration and Finance	 		 		 	Vice Chancellor and General Councel
			
	APPROVED AS TO CONTENT	 		 	APPROVED AS TO FORM
					
	By:	 	 /s/ William Doty
	 		 	By:	 	 /s/ Dudley R. Dobie, Jr.

		 	William Doty	 		 		 	Dudley R. Dobie, Jr.
		 	Director, Technology Development	 		 		 	Manager, Intellectual Property
				
	Argus Pharmaceuticals, Inc.	 		 		 	
					
	By:	 	 /s/ David Leech
	 		 		 	
		 	David Leech	 		 		 	
		 	President	 		 		 	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 AMENDMENT NO.6 TO THE 
 PATENT AND TECHNOLOGY LICENSE AGREEMENT 
 This AMENDMENT NO. 6 effective this 10th day of August , 2004
(“AMENDMENT NO. 6 EFFECTIVE DATE”) to the ORIGINAL LICENSE as defined below, is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose
address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (hereafter “UTMDACC”), a component institution of SYSTEM, and ARONEX PHARMACEUTICALS, INC., a Delaware corporation
having a principal place of business located at 3 Forbes Road, Lexington, Massachusetts 02421 (“LICENSEE”), a wholly owned subsidiary of ANTIGENICS INC., a Delaware corporation. BOARD and LICENSEE may be referred to hereafter collectively
as the “PARTIES.” 
 RECITALS 
  

	A.	BOARD and ARGUS PHARMACEUTICALS, INC., executed an Exclusive License Agreement dated effective as of July 22, 1988 (such Exclusive License Agreement, as amended, referred to
herein as the “ORIGINAL LICENSE”); 

  

	B.	LICENSEE is the successor in interest to ARGUS PHARMACEUTICALS, INC.; 

  

	C.	The PARTIES have reached an agreement to return rights to certain technologies to BOARD (“RETURNED TECHNOLOGY,” as defined below); 

  

	D.	The PARTIES have further agreed that LICENSEE will provide certain information relating to the RETURNED TECHNOLOGY to UTMDACC; 

 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the parties hereby agree to the following:

 AMENDED TERMS 
  

	1.	Schedule Ito the ORIGINAL LICENSE is hereby amended to exclude the RETURNED TECHNOLOGY (as defined below). The amended Schedule I is attached hereto. 

  

	2.	Paragraph lB. of the ORIGINAL LICENSE shall be replaced in its entirety with the following: 

  

	 	B.	The term “Licensed Subject Matter” shall mean the subject matter of the patents and patent applications listed on Schedule I, together with any invention, discovery,
know-how, process, procedure, method, protocol, formula, technique, software, design, drawing, data, devices, specifications, sketches or other technical information directed thereto conceived, discovered, or reduced to practice by the
Researchers/Inventors, as of the date hereof (July 22, 1988), irrespective of whether other persons jointly participate in such conception, discovery or reduction to practice, and Related Technology (as defined in Paragraph I. C. herein) to be
conceived, discovered, or reduced to practice as the result of funding provided under LICENSEE’s sponsored research program, as provided in the Research and Development Contract (“R & D Contract”) 

  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment
request. An unredacted version of this agreement has been filed separately with the Commission. 

	 	 
between LICENSEE and UTMDACC, attached hereto as Exhibit I and incorporated herein, and all processes, compositions, uses and Products resulting therefrom,
and other subject matter that was Licensed Subject Matter under the ORIGINAL LICENSE (including amendments thereto); provided that, notwithstanding the foregoing, the term “Licensed Subject Matter” shall not include any RETURNED
TECHNOLOGY. 

  

	3.	Paragraph I.C. of the ORIGINAL LICENSE shall be replaced in its entirety with the following: 

  

	 	C.	The term “Related Technology” when used herein shall mean any invention, discovery, know-how, trade secret, or technical information conceived, discovered, or reduced to
practice as the result of funding under and during the term of the R & D Contract. Notwithstanding the foregoing, the term “Related Technology” shall not include any invention, discovery, know-how, trade secret, or technical
information directed to or encompassing any RETURNED TECHNOLOGY. 

  

	4.	Paragraph I.D. of the ORIGINAL LICENSE shall be replaced in its entirety with the following: 

  

	 	D.	The term “BOARD Patent Rights,” when used herein, shall mean those United States and foreign patents and patent applications or prospective patent applications, which
relate to the Licensed Subject Matter (as defined in Paragraph I. B. herein), any technology that is an infringement thereof (except as provided in Paragraph 5.5 of the R & D Contract), and Improvements (as defined in Paragraph I. L. herein)
that are the subject of any patent or patent application, in which BOARD now has or in the future acquires any interest during the term of this Agreement or during the term and arising as a result of the R & D Contract. The term “BOARD
Patent Rights” shall not include patents, patent applications or prospective applications directed to any RETURNED TECHNOLOGY. 

  

	5.	Paragraph I. E. of the ORIGINAL LICENSE shall be replaced in its entirety with the following: 

  

	 	E.	The term “BOARD Technical Information,” when used herein, shall mean all Licensed Subject Matter and all Improvements that are not subsumed within the BOARD Patent Rights.
The term “BOARD Technical Information” shall not include any RETURNED TECHNOLOGY. 

  

	6.	Paragraph I.L. of the ORIGINAL LICENSE shall be replaced in its entirety with the following: 

  

	 	L.	The term “Improvement” where used herein means any change or modification to the Licensed Subject Matter, and any compositions, Products and uses resulting therefrom
(together with all other patents and patent applications, including any division, continuation, continuation-in-part or reissue thereof, or substitute therefor and the patents that may issue from such changes or modifications), conceived,
discovered, or reduced to practice, in whole or in part by the Researchers/Inventors, irrespective of whether other persons jointly participate in such conception, discovery or reduction to practice, to the extent that such change or modification
relates to the Licensed Subject Matter. The term “Improvement” shall not include any RETURNED TECHNOLOGY. 

  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with
the Commission. 

	7.	New Paragraph I.M. shall be added to the ORIGINAL LICENSE as follows: 

  

	 	M.	The term “RETURNED TECHNOLOGY” shall mean LICENSEE’s rights, including BOARD PATENT RIGHTS and rights in BOARD TECHNICAL INFORMATION, in and to the subject matter
listed on Schedule II (attached to this AMENDMENT NO. 6) and any U.S. or foreign patents, patent applications (including divisionals, continuations, reissues, reexaminations or extensions thereof) and other intellectual property directed thereto.

  

	8.	New Paragraph II. G. shall be added to the ORIGINAL LICENSE as follows: 

  

	 	G.	In addition to its rights as set forth in the R&D Contract and elsewhere in this Agreement, UTMDACC and BOARD further reserve the right to use (but not to transfer to third
parties) LICENSED SUBJECT MATTER solely for noncommercial research, teaching, patient care at The University of Texas facilities, including UTMDACC facilities, and other non-commercial educationally-related purposes. Notwithstanding any provisions
to the contrary in Article VIII or elsewhere in the Agreement, UTMDACC and BOARD reserve the right to publish the general scientific findings from research related to LICENSED SUBJECT MATTER, with due regard for the protection of LICENSEE’s
confidential information as follows. UTMDACC will submit the manuscript of any proposed publication to LICENSEE at least [**] days before publication, and LICENSEE shall have the right to review and comment upon the publication in order to protect
LICENSEE’s confidential information. Upon LICENSEE’s request, publication may be delayed up to [**] additional days to enable LICENSEE to secure adequate intellectual property protection of LICENSEE’s confidential information or other
intellectual property that would otherwise be affected by the publication. 

  

	9.	New Paragraph II.H. shall be added to the ORIGINAL LICENSE as follows: 

  

	 	H.	It is expressly understood and agreed that the Grant of Rights set forth in Paragraphs II.A. and II.B. above shall not include the RETURNED TECHNOLOGY. 

  

	10.	New Paragraph II.J. shall be added to the ORIGINAL LICENSE as follows: 

  

	J.	1. Through a computer search of its file system database in 2003, LICENSEE has identified approximately 526 boxes of documents (the “Documents”) that, based on the labels
on the boxes, appear to relate to the RETURNED TECHNOLOGY. Promptly after execution of this Amendment, LICENSEE shall send the Documents to UTMDACC. UTMDACC shall pay the costs of shipping the documents. The Documents that relate to the RETURNED
TECHNOLOGY shall be referred to as “Returned Technology Information.” 

 2. BOARD and UTMDACC shall maintain the
Returned Technology Information in confidence and shall not disclose it to third parties, except that BOARD and 
  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with
the Commission. 

 
UTMDACC may disclose Returned Technology Information: (a) when required by applicable laws, provided that BOARD or UTMDACC provides LICENSEE with prior
written notice of such disclosure and affords LICENSEE a reasonable opportunity to obtain a protective order; and (b) as needed or required in connection with the securing of necessary governmental authorization for BOARD, UTMDACC, their
licensees or sublicensees to manufacture, use, sell, or offer to sell products using the RETURNED TECHNOLOGY, provided that any such disclosure by BOARD or UTMDACC shall be made in accordance with applicable legal requirements, including, without
limitation, requirements related to confidentiality of health-related information. This obligation to maintain Returned Technology Information in confidence shall not apply to information that: (i) was in the public domain at the time of
disclosure; (ii) later became part of the public domain through no act or omission of UTMDACC or BOARD, their employees, agents, successors, or assigns; (iii) UTMDACC or BOARD can show was in its possession at the time of disclosure and
which was not acquired, directly or indirectly from LICENSEE; (iv) was lawfully disclosed to UTMDAC or BOARD by a third party having the right to disclose it; (v) was already known by UTMDACC or BOARD at the time of disclosure; or
(vi) was independently conceived, discovered, or reduced to practice. 
 3. To the extent authorized by the Constitution and laws of the
State of Texas, UTMDACC and BOARD assume all liability for any claim, loss, cost, damage, fee or expense (“Losses”) arising out of any use or disclosure of the Returned Technology Information by BOARD or UTMDACC. LICENSEE shall not be
liable to UTMDACC or BOARD for any claim or demand made by UTMDACC or BOARD, or made against UTMDACC or BOARD by a third party, due to or arising from the use or disclosure of the Returned Technology Information by UTMDACC or BOARD. 
 4. UTMDACC shall be under no obligation or duty to determine whether or not the Documents relate to RETURNED TECHNOLOGY. However, should UTMDACC determine
that certain of the Documents do not relate to the RETURNED TECHNOLOGY, UTMDACC shall notify LICENSEE, and, upon LICENSEE’s request and at LICENSEE’s expense, will return such Documents to LICENSEE. LICENSEE shall pay UTMDACC the costs of
shipping the Documents and shall pay reasonable expenses incurred by UTMDACC in segregating out the documents, provided that UTMDACC, in its notice to LICENSEE under the preceding sentence, notified LICENSEE that UTMDACC reasonably expected to incur
such expenses and gave the estimated amount of such reasonable expenses. 
 5. UTMDACC shall maintain the Documents for at least [**] years
after the AMENDMENT NO. 6 EFFECTIVE DATE and, upon reasonable written notice and during regular business hours, shall allow LICENSEE full access to the Documents for examination and copying, at LICENSEE’s expense. 
 6. Notwithstanding any provision herein to the contrary, BOARD and UTMDACC may disclose the Returned Technology Information to third parties that are
interested in licensing the RETURNED TECHNOLOGY, provided that such third party agrees in writing to maintain the Returned Technology Information as confidential and only use it for the limited purpose of due diligence review to determine whether to
enter into such license. Additionally, BOARD and UTMDACC may disclose Returned Technology Information to a third party that licenses the RETURNED TECHNOLOGY (a “Third Party Licensee”), provided that said third party agrees in writing to
the following terms, or such other terms approved in writing by LICENSEE: 
  

	 	A)	to maintain the Returned Technology Information in confidence and not use or disclose it except for the purposes, and subject to the limitations, set forth in subparagraphs II.J.2
(a)-(b) above; 

  
 [**] = Portions of this agreement have been
omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

	 	B)	to indemnify and hold LICENSEE and its directors, officers, employees, agents and Subsidiaries harmless against any Losses arising out of any use or disclosure of the Returned
Technology Information by the Third Party Licensee or by any person or entity to which the Third Party Licensee has disclosed or transferred the Returned Technology Information; 

  

	 	C)	to comply with the requirements set forth in subsection II.J.4 and 5 for any Documents in its possession; and 

  

	 	D)	that LICENSEE is a third party beneficiary of the foregoing provisions II.J.6.(A), (B), and (C) with the authority to enforce the provisions against the Third Party Licensee.

 UTMDACC shall provide LICENSEE with a copy of any written agreement referred to in the preceding sentence with a Third Party
Licensee. This obligation to maintain Returned Technology Information in confidence shall not apply to information that: (i) was in the public domain at the time of disclosure; (ii) later became part of the public domain through no act or
omission of UTMDACC or BOARD, their employees, agents, successors, or assigns; (iii) UTMDACC or BOARD can show was in its possession at the time of disclosure and which was not acquired, directly or indirectly from LICENSEE; (iv) was
lawfully disclosed to UTMDAC or BOARD by a third party having the right to disclose it; (v) was already known by UTMDACC or BOARD at the time of disclosure; or (vi) was independently conceived, discovered, or reduced to practice.

 7. LICENSEE DOES NOT MAKE ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE RETURNED MATERIAL INFORMATION OR RETURNED
TECHNOLOGY AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SAFETY OR LAWFULNESS OF USE, ACCURACY, RELIABILITY, OR NONINFRINGEMENT OF THIRD
PARTY PATENTS, WITH RESPECT TO THE FOREGOING. 
 8. In consideration of receiving the Returned Technology Information, UTMDACC hereby agrees
to pay to LICENSEE [**] percent [**] of any consideration that BOARD and/or UTMDACC receive as a result of and attributable to licensing or otherwise transferring rights in some or all of the RETURNED TECHOLOGY, including without limitation
royalties, license fees, milestone payments, equity, and the fair market value of non-cash considerations (“Returned Technology Consideration”). UTMDACC will maintain records of any Returned Technology Consideration received and will
provide a report to LICENSEE within [**] days of the close of each calendar year identifying the amount of Returned Technology Consideration received during that calendar year, on a product-by-product basis, and shall provide payment with said
report of LICENSEE’s share of Returned Technology Consideration. 
  
 [**] =
Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 11. New Paragraph 11.1. shall be added to the ORIGINAL LICENSE as follows: 
 1. LICENSEE hereby grants to BOARD, for the term of the Agreement, a worldwide, exclusive solely for use in the [**] Field (as defined below),
royalty-free license, with right to sublicense for value, the subject matter of U.S. Application No. [**] (MDA[**] CON) and its foreign equivalents (collectively the “Subject Patent”), including the right to manufacture, use, market and/or
sell products or services covered by the Subject Patent, and any divisonals, continuations, resissues, reexaminations or extensions thereof. The term “[**] Field” as used herein shall include: (1) compositions containing, as an active
ingredient, [**] or related [**] agents, such as those exemplified by [**], its derivatives or analogs; (2) methods of delivering said compositions to a patient, tissue or other target; and (3) methods for manufacturing such compositions.
No other rights to the Subject Patent are granted herein by LICENSEE to BOARD. 
 12. Paragraph VI. E. 3. of the ORIGINAL LICENSE shall be replaced in its
entirety with the following: 
  

	 	3.	Subject to Paragraph VI.E.2, LICENSEE shall discontinue, and shall cause its Subsidiaries and sublicensees to discontinue, the manufacture, use, marketing and sale of Products. Upon
termination, UTMDACC will accept as successors to LICENSEE under this Agreement each of LICENSEE’s sublicensees that, as of the date of termination, is not in material breach of its sublicense; provided that such sublicensee consents in writing
to be bound by all of the terms and conditions of this Agreement. Notwithstanding the foregoing, upon termination LICENSEE shall immediately discontinue use of the Names. 

 13. Paragraph VII.A. of the ORIGINAL LICENSE shall be replaced in its entirety with the following: 
  

	 	A.	Any request, notice, report, approval, payment, communication or other document required or permitted under this Agreement will be in writing (except in the case of verbal
communications and teleconferences updating either Party as to the status of work hereunder), and will be deemed given (1) when delivered personally; (2) when sent by confirmed facsimile (followed by the actual document sent by commercial
express courier specifying next day delivery, with written verification of receipt); (3) five (5) business days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (4) one (1) day
after deposit with a commercial express courier specifying next day delivery, with written verification of receipt. All communications will be sent to the address set forth below or such other address as either Party may designate from time to time
in accordance with this Paragraph VII.A. 

  

			
	If to UTMDACC:	 	The University of Texas M. D. Anderson Cancer Center
		 	Office of Technology Commercialization
		 	7515 S. Main, Suite 490, Unit 0510
		 	Houston, TX 77030
		 	ATTENTION: William I. Doty

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

			
	with copy to:	 	BOARD OF REGENTS
		 	The University of Texas System
		 	201 West 7th Street
		 	Austin, TX 78701
		 	ATTENTION: Office of General Counsel
		
	If to Licensee:	 	VP, Business Development
		 	c/o Antigenics Inc.
		 	3 Forbes Road
		 	Lexington, MA 02421
		
	With a copy to:	 	Senior Attorney
	            c/o Antigenics Inc.
	            3 Forbes Road
	            Lexington, MA 02421

 (or at such other address in care of such other person as hereafter shall be designated in writing by any party).

  

	14.	Paragraph X.A. of the ORIGINAL LICENSE shall be replaced in its entirety with the following: 

  

	 	A.	This Agreement may not be assigned by any party, without the prior written consent of the other parties, which consent shall not be unreasonably withheld, provided that LICENSEE may
assign this Agreement without the consent of the other parties to a Subsidiary, or to any purchaser or transferee of all or substantially all of LICENSEE’s business to which this Agreement relates, or to the surviving entity in the case of a
merger or change of control transaction or series of transactions, and provided further, that nothing shall prevent LICENSEE from entering into sublicensing agreements, or the sale of marketing rights as herein provided, with other parties. This
Agreement shall be binding upon and inure to the benefit of BOARD, UTMDACC, LICENSEE and their respective permitted assigns and sublicenses and successors in interest. 

 LICENSEE agrees that it shall provide copies of all sublicenses and notices of any assignments to UTMDACC. 
  

	15.	New Paragraph XIV. D. shall be added to the ORIGINAL LICENSE as follows: 

  

	 	D.	LICENSEE acknowledges that UTMDACC and BOARD are agencies of the State of Texas and, under the Constitution and laws of the State of Texas, possess certain rights and privileges and
are subject to certain limitations and restrictions. Notwithstanding any provision herein, nothing in this Agreement is intended to be, nor may it be construed to be, a waiver of the sovereign immunity of the State of Texas. Moreover,
notwithstanding the generality or specificity of any provision herein, the provisions of this Agreement are enforceable only to the extent authorized by the Constitution and laws of the State of Texas; accordingly, the provisions of this Agreement
will not be enforceable to the extent (i) any provision conflicts with or is not authorized by the Constitution or laws of the State of Texas, or (ii) UMDACC and/or BOARD did not have the power or authority to agree to such provision.

  
 [**] = Portions of this agreement have been omitted pursuant to
a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 16. From and after the AMENDMENT NO.6 EFFECTIVE DATE, this AMENDMENT NO. 6, including Schedules I and II hereto,
supersedes and replaces the letter from ANTIGENICS INC. to UTMDACC dated April 21, 2003. 
 OTHERWISE, the terms and provisions of the ORIGINAL LICENSE
(including Amendment No. 1, Amendment No. 2, (dated October 8, 1990), Amendment No. 2 (dated July 9, 1993), Amendment No. 3, and Amendment No. 4) shall remain in full force and effect, provided, however, in the
event of a conflict in the terms and conditions between this AMENDMENT NO. 6 and the foregoing ORIGINAL LICENSE, the terms and conditions of this AMENDMENT NO. 6 shall prevail. 
 [The rest of this page has intentionally been left blank.] 
  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with
the Commission. 

 Signature Page — Amendment No. 6 to Exclusive License Agreement 
 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute this AMENDMENT NO.6. 
  
  

									
	 THE UNIVERSITY OF TEXAS
 M.D. ANDERSON CANCER
CENTER
	 		 	 THE BOARD OF REGENTS OF THE
 UNIVERSITY OF
TEXAS SYSTEM

					
	By:	 	 /s/ Leon Leach
	 		 	By:	 	 /s/ John Mendelsohn

		 	Leon Leach	 		 		 	John Mendelsohn, M.D.
		 	Executive Vice President	 		 		 	President
		 	M.D. Anderson Cancer Center	 		 		 	
					
	By:	 	 /s/ William J. Doty
	 		 		 	
		 	William J. Doty	 		 		 	
		 	Managing Director	 		 		 	
		 	Office of Technology Commercialization	 		 		 	
		 	M.D. Anderson Cancer Center	 		 		 	

			
	
	ARONEX PHARMACEUTICALS, INC.:
		
	By:	 	 /s/ Garo Armen

			
	Printed Name:	 	Garo Armen

			
	Title:	 	CEO

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

									
	 	    	 	    	 	    	 Patent Schedules

	 MDA No.
	    	 UTSC No.
	    	 U.S Patent
	    	 Foreign
	    	 Title

	Schedule I: Antigenics Retaining	    		    	
					
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
			
	Schedule II: Antigenics Returning	    		    	
					
	MDA[**]	    	[**]	    	[**]	    	[**]	    	[**]
	MDA[**]	    	[**]	    	[**]	    	[**]	    	[**]
	MDA[**]	    	[**]	    	[**]	    	[**]	    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]
	MDA[**]	    	[**]	    	[**]	    		    	[**]

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

									
	 	    	 	    	 	    	 Patent Schedules

	 MDA[**]
	    		    	[**]	    	[**]	    	[**]
	 MDA[**]
	    	[**]	    	[**]	    		    	[**]
	 MDA[**]
	    	[**]	    	[**]	    		    	[**]
	 MDA[**]
	    	[**]	    	[**]	    		    	[**]
	 MDA[**]
	    	[**]	    	[**]	    		    	[**]
	 MDA[**]
	    	[**]	    	[**]	    	[**]	    	[**]

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 AMENDMENT NO.7 TO THE PATENT AND 
 TECHNOLOGY LICENSE AGREEMENT 
 This AMENDMENT NO. 7 effective this 1st day of December 2005
(“AMENDMENT NO.7 EFFECTIVE DATE”) to the ORIGINAL LICENSE as defined below, is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose
address is 201 West Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (hereinafter “UTMDACC”), a component institution of SYSTEM, and ARONEX PHARMACEUTICALS, INC., a Delaware corporation having
a principal place of business located at 3 Forbes Road, Lexington, Massachusetts 02421 (“LICENSEE”), a wholly-owned subsidiary of ANTIGENICS INC., a Delaware corporation. BOARD and LICENSEE may be referred to hereafter collectively as the
“PARTIES.” 
 RECITALS 
 A.
BOARD and LICENSEE (as successor in interest to ARGUS PHARMACEUTICALS, INC.) are parties to that certain Exclusive License Agreement dated effective as of July 22, 1988 (such Exclusive License Agreement, as amended as described in more detail
below, referred to herein as the “ORIGINAL LICENSE”); 
 B. BOARD and LICENSEE desire to further amend the ORIGINAL LICENSE. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the PARTIES hereby agree to the following:

 AMENDED TERMS 
 1. The last sentence of
Paragraph II.J.8 of the ORIGINAL LICENSE shall be deleted in its entirety and replaced with the following: 
 UTMDACC shall provide such
payments to LICENSEE within [**] days of UTMDACC’S and/or BOARD’S receipt of such Returned Technology Consideration. In addition, UTMDACC will maintain records of any Returned Technology Consideration received and will provide a report to
LICENSEE within [**] days of the close of each calendar year, identifying the amount of Returned Technology Consideration received during that calendar year, on a product-byproduct basis, and the consideration owed and paid to LICENSEE with respect
thereto. 
  
 [**] = Portions of this agreement have been omitted pursuant to a
confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 
 1 

 2. For the avoidance of doubt, the PARTIES acknowledge and agree that, prior to the AMENDMENT NO.7 EFFECTIVE DATE, the
ORIGINAL LICENSE was amended as follows: 
  

	 	•	 	 Amendment No.1 to the Exclusive License Agreement dated March 12, 1990 (“AMENDMENT NO. 1”) 

  

	 	•	 	 Amendment No.2 to the Exclusive License Agreement dated October 8, 1990 (“AMENDMENT NO.2”) 

  

	 	•	 	 Amendment No.2 to the Exclusive License Agreement dated July 9, 1993 (“AMENDMENT NO.3”) 

  

	 	•	 	 Amendment No.3 to the Exclusive License Agreement dated December 9, 1993 (“AMENDMENT NO.4”) 

  

	 	•	 	 Amendment No.4 to the Exclusive License Agreement dated August 9, 1994 (“AMENDMENT NO.5”) 

  

	 	•	 	 Amendment No.6 to the Exclusive License Agreement dated August 10, 2004 (“AMENDMENT NO.6”) 

 3 The PARTIES acknowledge and agree that, except as set forth in this AMENDMENT NO.7, the terms and conditions of the ORIGINAL LICENSE (including AMENDMENT NOS. 1-6)
shall remain in full force and effect. 
 4 This AMENDMENT NO.7 may be executed by the PARTIES hereto in separate counterparts, each of which when so
executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument. Each counterpart may consist of a number of copies hereof each signed by less than all, but together signed by all of the
PARTIES hereto. 
 [The rest of this page has intentionally been left blank.] 
  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement
has been filed separately with the Commission 
 2 

 IN WITNESS WHEREOF, the PARTIES hereto have caused their duly authorized representatives to execute this AMENDMENT NO.7.

  

									
	 THE UNIVERSITY OF TEXAS
 M. D. ANDERSON
CANCER CENTER
	 		 	 THE BOARD OF REGENTS OF
 UNIVERSITY OF
TEXAS SYSTEM

					
	By:	 	 /s/ Leon Leach
	 		 	By:	 	 /s/ John Mendelsohn

		 	Leon Leach	 		 		 	John Mendelsohn, M.D.
		 	Executive Vice President	 		 		 	President
		 	M.D. Anderson Cancer Center	 		 		 	M.D. Anderson Cancer Center
	Date:	 	11/29/05	 		 	Date:	 	12/1/03

							
			
	APPROVED AS TO CONTENT:	 		 	
				
	By:	 	 /s/ Christopher C. Capelli
	 		 	
		 	Christopher C. Capelli	 		 	
		 	Vice President, Technology Transfer	 		 	
		 	Office of Technology Commercialization	 		 	
		 	M.D. Anderson Cancer Center	 		 	
	Date:	 	10/26/05	 		 	

			
	
	ARONEX PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Russell Herndon

	Name:	 	Russell Herndon
	Title:	 	President
	Date:	 	10/24/05

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 LETTER AGREEMENT 
 This Letter Agreement is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on
behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (hereafter “UTMDACC” or “UTSCC”), a component institution of SYSTEM, and ARONEX PHARMACEUTICALS, NC., a Delaware corporation having an address at 3 Forbes Road,
Lexington, MA 02421 (“ARONEX PHARMACEUTICALS”), a wholly owned subsidiary of ANTIGENICS NC., a Delaware corporation (“LICENSEE”). 
 WHEREAS, UTMDACC and LICENSEE executed an Exclusive License Agreement on July 22, 1988, (the “ORIGINAL LICENSE”) as amended by Amendment Number 1 dated effective March 12, 1990; and as further amended by Amendment Number
2, dated effective October 8, 1990; Amendment Number 2, dated effective December 9, 1993; Amendment Number 3, dated effective July 9, 1993; Amendment Number 4, dated effective August 9, 1994; and Amendment Number 6, dated
effective 10th day of August, 2004. 
 WHEREAS, pursuant to the ORIGINAL LICENSE, ARONEX PHARMACETICALS engaged in the development of Annamycin, among other
technologies, pursuant to the ORIGINAL LICENSE and completed Phase II clinical testing of Annamycin in breast cancer. 
 WHEREAS, the parties have reached an
agreement to return rights to certain technologies, including [**], to BOARD (“RETURNED TECHNOLOGIES,” as defined in Amendment 6 to the ORIGINAL LICENSE) and the parties have further agreed that LICENSEE will provide certain information
relating to the RETURNED TECHNOLOGIES to UTMDACC and LICENSEE shall not be responsible for any liability related to future use the RETURNED TECHNOLOGIES. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the parties hereby agree to the following: 
 1. No Other Representations or Warranties. THE MATERIAL IS AND WAS PROVIDED TO UTMDACC “AS IS.” LICENSEE DOES NOT MAKE ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE MATERIAL AND EXPRESSLY
DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, TITLE, FITNESS FOR A PARTICULAR PURPOSE OR USE, INCLUDING WITHOUT LIMITATION FITNESS FOR HUMAN USE, QUALTIY AS TO THE MATERIAL, OR ANY PART
THEREOF, WITH RESPECT TO THE FOREGOING. 
 2. Limitation of Liability. In no event shall LICENSEE be liable to UTMDACC, or any of its affiliates, for any
damages whatsoever, including without limitation direct, indirect, consequential, special, or incidental damages, arising out of UTMDACC or any affiliate’s use of the MATERIAL, even if UTMDACC or any affiliate has been advised of the
possibility of such damage and whether or not such damages are reasonably foreseeable. 
  
 [**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 3. Indemnification. To the extent not prohibited under law, UTMDACC will indemnify, defend and hold harmless LICENSEE and
its affiliates, officers, directors, employees and agents (“ARONEX PHARMACEUTICALAS Indemnitees”) from and against any liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) incurred or
imposed upon LICENSEE Indemnitees or any one of them in connection with any claims, suits, actions, losses, demands or judgments arising out of UTMDACC‘s use of the MATERIAL, including without limitation any theory of product liability
(including without limitation ion actions in the form or tort, warranty or strict liability) concerning any product developed using or incorporating the MATERIAL. 
 4. Representation and Warranty. UTMDACC represents, warrants and covenants that it shall use the MATERIAL in compliance with all applicable laws and regulations, including but not limited to those relating to biotechnological research and
the handling and containment of biohazardous materials. 
 5. Materials Returned and Accepted. The parties acknowledge and agree that pursuant to the
agreements referenced above, LICENSEE has returned certain amounts of Annamycin, in its physical form, (“MATERIAL”) to UTMDACC, and UTMDACC has accepted the MATERIAL as described in Attachment 1 to this Letter Agreement, attached hereto.

 6. Reimbursement. UTMDACC shall reimburse LICENSEE for the return of the MATERIALS, as described in Attachment 2 to this Letter Agreement, attached
hereto. 
 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute this Letter Agreement. 
  

			
	 THE UNIVERSITY OF TEXAS
 M. D.ANDERSON CANCER
CENTER

		
	By	 	 /s/ Leonard A. Zwelling

		 	Leonard A. Zwelling, M.D, M.B.A.
		 	Vice President, Research Administration
	
	ARONEX PHARMACEUTICALS:
		
	By	 	 /s/ Russell Herndon

			
	Printed Name:	 	Russell Herndon

			
	Title:	 	President

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Attachment I to Letter Agreement (page 1/2) 
 [**] SHIPMENT 10/03/2003 
  

									
	 Box 1
	  		  		  		  	Vials
	 522-03-9H-001
	  	5 cases at	  	30	  	150	  	
	 50mg
	  		  		  		  	
	 Total vials
	  		  		  	150	  	150
					
	 327l1197
	  	1 case at	  	63	  	63	  	
	 10mg
	  		  		  		  	
	 Total vials
	  	 	  	 	  	63	  	63
					
	 Box 2
	  		  		  		  	Vials
	 522-03-94-001
	  	6 cases at	  	30	  	180	  	
	 50mg
	  	1 case at	  	9	  	9	  	
	 Total vials
	  	 	  	 	  	189	  	189
					
	 Box 3
	  		  		  		  	Vials
	 522-02-8A-001
	  	6 case at	  	63	  	378	  	
	 10mg
	  		  		  		  	
	 Total vials
	  	 	  	 	  	378	  	378
					
	 Box 4
	  		  		  		  	Vials
	 522-02-8A-001
	  	3 case at	  	63	  	189	  	
	 10mg
	  		  		  		  	
	 Total vials
	  		  		  	189	  	189
					
	 327l197
	  	1 case at	  	60	  	60	  	
	 10mg
	  		  		  		  	
	 Total vials
	  		  		  	60	  	60
					
	 522-01-8K-004
	  	1 case at	  	11	  	11	  	
	 50mg
	  		  		  		  	
	 Total vials
	  		  		  	11	  	11
					
	 327l197
	  	1 case at	  	5	  	5	  	
	 50mg
	  		  		  		  	
	 Total vials
	  	 	  	 	  	5	  	5
	 Total
	  		  		  		  	1,045

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Attachment I to Letter Agreement (page 2/2) 
 [**] SHIPMENT 10/03/2003 
  

											
	 Box 5
	  		  		  		  	Vials	  	mgs
	 327l1197
	  	5 cases at	  	63	  	315	  		  	
	 10mg
	  	1 case at	  	53	  	53	  		  	
	 Total vials
	  	 	  	 	  	368	  	368	  	3680
						
	 Box 6
	  		  		  		  		  	
	 522-01-8B-002
	  	2 case at	  	25	  	50	  		  	
	 50mg
	  	1 case at	  	24	  	24	  		  	
	 Total vials
	  	 	  	 	  	74	  	74	  	3700

 One box of jars containing various intermediate samples from Kris Dziewiszcek’s lab via QC. 
 RAW MATERIAL SHIPMENT 10114103 
  

							
	Lot# P1885 R00580	 	1 package at	 	95.579	    	grams
	Lot # P1886 R00581	 	2 package at	 	105.5	    	grams
		 		 	201.079	    	

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Attachment 2 to Letter Agreement 
  

					
	Antigenics Inc.	  	Invoice	  	INVMDAOO1
	3 Forbes Road	  	Date	  	10/29/2003
	Lexington, MA 02421	  	Customer ID	  	MD Anderson
		  	Page	  	1

 Bill To: 
 U of Texas 
 MD Anderson 
  

			
	Purchase Order No.	  	Payment Terms
		  	NET 30

  

								
	 Description
	  	Units	  	Unite Price	  	 	Ext. Price
	 Labor hours for defacing labels for [**] shipment (1570 units)
	  	16.00	  	20.00	  	$	320.00
	 Insulated cartons
	  	6.00	  	14.00	  	$	84.00
	 Dangerous goods shippers
	  	2.00	  	28.00	  	$	56.00
	 Insulated cartons
	  	2.00	  	44.00	  	$	88.00
	 Dry ice pellets (200 pounds)
	  	200.00	  	2.00	  	$	400.00
	 Gel pack cartons
	  	5	  	7.41	  	$	37.05
	 FedEx freight cost
	  		  		  	$	2,254.62
	 Marken freight cost (2 cartons of dangerous goods)
	  		  		  	$	759.80
			
		  	Subtotal	  	$	3,999.47
		  	Misc	  	 	—  
		  	Tax	  	 	—  
		  	Freight	  	 	—  
		  	Trade Discount	  	 	—  
		  	Total	  	$	3,999.41

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]